{
  "0": {
    "score": 3.0,
    "explanation": "3: The model answer identifies the mechanism (dopamine receptor agonist/vasodilator) and provides relevant detail, but it omits the key reference class \"adrenergic agonists,\" covering about 70-89% of key facts."
  },
  "1": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant, correct information about supportive care and shared decision-making without any inaccuracies or omissions."
  },
  "2": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on iron levels, storage, and neurotransmitter metabolism, omitting the key fact that electrolyte activity and neuronal/muscular excitability are directly affected by the compound’s molecular action; it also does not mention monitoring for electrolyte disturbances, which is central to the reference answer."
  },
  "3": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine PET/CT is not recommended, and appropriately describes when PET/CT may be used; additional explanations are accurate and clinically relevant."
  },
  "4": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies ergosterol as the drug target and describes the mechanism of binding and membrane disruption, but it does not specify \"ergosterol synthesis inhibition\" as the molecular process, instead describing direct binding; this misses the key fact that the question asks about inhibition of synthesis, not just binding."
  },
  "5": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that adjuvant EBRT is considered with positive margins and that patient-specific factors are important, but it overstates that EBRT is \"generally recommended regardless of prior chemotherapy,\" missing the nuance that its use is not routine for all and may depend on prior therapy and risk factors."
  },
  "6": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the importance of pathological confirmation and multidisciplinary discussion, but incorrectly states that clinical (radiological) staging is typically sufficient for treatment decisions, which contradicts the reference's requirement for pathological confirmation before assigning N3 status; this represents a moderate factual inaccuracy."
  },
  "7": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the drug as pyrantel pamoate and its action as a depolarizing neuromuscular blocker activating nicotinic acetylcholine receptors, but it omits the key reference mechanism of cholinesterase inhibition, which is central to the question."
  },
  "8": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly identifies SSTR2 instead of SSTR5 as the primary receptor, covering most other key facts but missing the specific receptor subtype, which is a moderate factual error."
  },
  "9": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that adjuvant therapy is generally indicated and discussing relevant considerations, but it equivocates on indication despite the reference stating it remains indicated if comorbidities are well-compensated, and overemphasizes individualization, leading to a minor omission of the clear recommendation."
  },
  "10": {
    "score": 3.0,
    "explanation": "3: The model answer provides a plausible mechanism (antimicrobial effects) but does not state that the precise molecular mechanism is not fully understood, which is the key fact in the reference; however, it does not contain unsafe or irrelevant content."
  },
  "11": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that RET inhibitors can be used after chemotherapy if a RET rearrangement is discovered, but incorrectly affirms that first-line use remains appropriate in this scenario, missing the key distinction that they are no longer considered first-line therapy after initial systemic treatment."
  },
  "12": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interleukin-6 receptor (IL-6R) as the direct target, matching the reference answer, and provides relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "13": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly emphasizing the urgency of symptom control with radiotherapy and the importance of molecular profiling for systemic therapy. It introduces a minor nuance about asymptomatic patients that is not in the reference but is clinically reasonable; however, this slight deviation and extra detail constitute a minor omission in directness, warranting a score of 4."
  },
  "14": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that adjuvant chemotherapy with trastuzumab is appropriate for metaplastic histology, directly contradicting the key fact that metaplastic breast cancer is an exception to standard recommendations; this is a major inaccuracy."
  },
  "15": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly emphasizing the importance of molecular profiling and the rarity of concurrent mutations, but it inaccurately suggests that ALK inhibitor use does not inherently depend on EGFR status, missing the key point that ALK inhibitor therapy presumes EGFR negativity; this is a minor but clinically relevant omission."
  },
  "16": {
    "score": 1.0,
    "explanation": "1: The model answer does not identify the correct class (serotonin antagonists) and instead focuses on botulinum toxin and anticholinergics, which are not the reference answer; it also contains some confusion about mechanism and class, making the response largely irrelevant to the specific question."
  },
  "17": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that surveillance frequency differs and provides the correct interval for surgical patients, but it omits the specific 3–6 month interval for post-radiotherapy surveillance, which is a key fact. It also adds some general but relevant context without clinical error."
  },
  "18": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 instead of CYP2C8 as the most relevant enzyme, which is a moderate factual error, though the rest of the explanation is relevant and accurate."
  },
  "19": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting the 0.6 cm threshold and that routine adjuvant trastuzumab is not established for tumors below this size, but it introduces ambiguity by suggesting flexibility and possible consideration for smaller tumors, which is not supported by guidelines and could be misleading."
  },
  "20": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario and that the agent is a direct-acting vasodilator with an incompletely understood mechanism, but it does not explicitly state \"unknown cellular or molecular interaction\" as required by the reference, and instead focuses on the drug class rather than the mechanistic classification."
  },
  "21": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that switching to crizotinib is justified and provides relevant rationale, but it omits that completing the current regimen is also an acceptable option per guidelines, thus missing a key fact."
  },
  "22": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts and provides additional relevant explanation about the importance of pathologic confirmation, but introduces a minor caveat about proceeding without confirmation in select cases, which is not mentioned in the reference and slightly weakens the absolute requirement stated."
  },
  "23": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly prioritizing re-resection if feasible and discussing chemoradiation as an alternative, with appropriate mention of concurrent versus sequential approaches and the need for individualized, multidisciplinary decision-making. However, it slightly overstates the preference for concurrent chemoradiation without clarifying that there is no definitive evidence of superiority over re-resection plus systemic therapy, which is a minor omission."
  },
  "24": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies lipoxygenase as the enzyme class, explains its role in leukotriene synthesis, and links inhibition to reduced inflammation and edema, matching all key reference facts with relevant, accurate elaboration."
  },
  "25": {
    "score": 2.0,
    "explanation": "2: The model answer omits the valid option of completing current systemic therapy, presenting immediate switch to crizotinib as the only appropriate action, which is a moderate factual omission. It also lacks mention of individualization based on response, tolerability, or urgency."
  },
  "26": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies RNA polymerase as the target, specifies the drug (fidaxomicin), accurately describes its local action and mechanism (inhibition of the sigma subunit and transcription initiation), and provides clinically relevant context without any inaccuracies or omissions."
  },
  "27": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacological class (nitrates/nitric oxide donors), accurately explains the mechanism (conversion to NO, increase in cGMP), and provides clinically relevant details without any inaccuracies or omissions."
  },
  "28": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly emphasizing that broad molecular profiling is not routinely indicated in squamous cell carcinoma but may be considered in select patients (e.g., minimal smoking history). However, it overstates the role of broad profiling by suggesting it \"should be considered\" for all, and does not clearly state that PD-L1 testing is standard, leading to some ambiguity and minor inaccuracies."
  },
  "29": {
    "score": 3.0,
    "explanation": "3: The model answer covers the general mechanism of nitroimidazoles and acknowledges that the exact molecular details are not fully resolved, but it overstates the current knowledge by specifying DNA as the primary target, whereas the reference emphasizes that the precise target remains unknown."
  },
  "30": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizing the need for individualized evaluation and management of each lesion, and noting that treatment may diverge from the standard pathway for a single T3, N1 lesion; all additional content is accurate and clinically relevant."
  },
  "31": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that amivantamab-vmjw use is not contingent on broad profiling but that comprehensive profiling is good practice to identify other actionable mutations; all additional content is correct and clinically relevant."
  },
  "32": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the IL-6 receptor as the molecular target and provides relevant clinical context, but does not specify the \"soluble interleukin-6 receptor subunit alpha\" as in the reference; this is a minor omission in specificity."
  },
  "33": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the role of radiotherapy for symptomatic brain metastases and the importance of systemic therapy, but it equivocates on prioritization and overemphasizes individualization, missing the reference's clear guidance that palliative radiotherapy is typically prioritized for symptomatic brain involvement."
  },
  "34": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizing that initial nodal status determines the need for adjuvant pertuzumab, and provides additional accurate, clinically relevant context without inaccuracies or omissions."
  },
  "35": {
    "score": 3.0,
    "explanation": "3: The answer covers the key fact that codeine acts via mu-opioid receptor agonism but introduces dextromethorphan and its mechanisms, which are not directly relevant to the reference answer. The explanation is mostly correct but somewhat diluted by extraneous detail, and only partially emphasizes the central opioid mu-receptor agonism as the main mechanism."
  },
  "36": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for SABR, and correctly states that surgery is not a viable option in this context, with no inaccuracies or omissions."
  },
  "37": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly states the restriction of the combination regimen to nonsquamous histology, and provides relevant additional details about alternative chemotherapy options for squamous cell carcinoma without inaccuracies or omissions."
  },
  "38": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that NTRK-targeted therapy is indicated only in the absence of other actionable driver mutations, and provides correct, relevant additional context without any inaccuracies or omissions."
  },
  "39": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly identifies TNF-alpha as the primary molecular target, missing the key fact that VEGF-A is responsible for the anti-angiogenic effect described; this is a major inaccuracy despite some relevant context."
  },
  "40": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies glucocorticoids and explains their inhibition of phospholipase A2, but it does not mention lipoxygenase inhibitors, which is the specific enzyme class asked for; thus, it covers the general mechanism but misses the key fact required by the question."
  },
  "41": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the staging and appropriateness of surgery, and adds relevant, correct details about patient evaluation and multidisciplinary discussion without any inaccuracies or omissions."
  },
  "42": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies FXR as the primary target instead of PPAR-delta, which is a moderate factual error. While it provides relevant background on FXR and its role in cholestatic liver disease, it misses the key fact required by the question."
  },
  "43": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly identifies the drug as alprostadil rather than papaverine and provides an inaccurate mechanism, missing the key fact that the mechanism is unknown; this constitutes a major inaccuracy."
  },
  "44": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies inhibition of dihydropteroate synthase and explains the role of PABA in folate synthesis, covering all key mechanistic details; however, it introduces some ambiguity by discussing sulfonamides and noting that metronidazole or clindamycin are more commonly used, which is extraneous and could cause minor confusion."
  },
  "45": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the relevant receptor families (including FGFR) and provides accurate, clinically relevant context, but it initially emphasizes PDGFR rather than FGFR as the primary target, which is a minor wording inaccuracy."
  },
  "46": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant supporting details (CNS penetration, ALEX trial), and contains no inaccuracies or omissions."
  },
  "47": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the glucocorticoid mechanism, including inhibition of phospholipase A2 and reduced leukotriene synthesis, but does not specifically mention inhibition of the lipoxygenase pathway as in the reference; it covers most key facts but lacks the precise pathway detail."
  },
  "48": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, correctly identifies serotonin receptor modulation, and provides relevant, accurate explanation without any errors or omissions."
  },
  "49": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the infection and the use of azole antifungals but incorrectly focuses on CYP51 inhibition rather than the reference's CYP17A1, and emphasizes competitive inhibition as the class, which is not the specific answer sought; this represents a moderate factual error and partial coverage of key facts."
  },
  "50": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the use of SERMs as standard, the exception of visceral crisis requiring chemotherapy, and provides additional correct and relevant details about ovarian suppression and other clinical considerations without inaccuracies or omissions."
  },
  "51": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the mechanism as inhibition of monoamine reuptake and mentions serotonin and norepinephrine, but \"serotonin-norepinephrine reuptake inhibitors (SNRIs)\" is not the most accurate class for weight loss agents like phentermine, and the example given is imprecise; about 70-89% of key facts are covered, but there are minor inaccuracies in drug classification."
  },
  "52": {
    "score": 2.0,
    "explanation": "2: The model answer provides relevant background and a partially correct mechanism but fails to align with the reference answer, which emphasizes that the precise cellular or molecular interaction is unknown; the model instead asserts a specific mechanism, representing a moderate factual inaccuracy."
  },
  "53": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies CYP3A4 induction as the mechanism, and provides additional accurate, relevant details about enzyme induction and its effect on contraceptive metabolism, with no inaccuracies or omissions."
  },
  "54": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, acknowledging the role of RET-targeted therapy but equivocates and incorrectly suggests chemotherapy remains standard despite actionable RET rearrangement, missing the current paradigm of prioritizing targeted therapy regardless of histology when molecular profiling is available."
  },
  "55": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate initiation of alectinib rather than completing current systemic therapy, omitting the key fact that therapy sequence prioritizes finishing current treatment; this is a major inaccuracy."
  },
  "56": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that prior multifocality or ineligibility for local therapy does not preclude concurrent chemoradiation for mediastinal nodal recurrence without prior thoracic radiotherapy, and provides relevant, accurate elaboration without inaccuracies or omissions."
  },
  "57": {
    "score": 3.0,
    "explanation": "3: The answer correctly emphasizes the antioxidant effect and glutathione replenishment, but omits explicit mention of the reduction/disruption of disulfide bonds, which is a key pharmacodynamic effect referenced in the question and reference answer."
  },
  "58": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the macrolide class and its mechanism, and relates it to Legionella, but does not explicitly state the broader pharmacologic class \"protein synthesis inhibitors,\" which is the key fact in the reference answer—a minor omission."
  },
  "59": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explaining that surgery is not preferred in patients with severely impaired pulmonary function and that SABR is the primary alternative; all additional details are accurate and clinically relevant."
  },
  "60": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that palliative chemotherapy assumes absence of metastatic disease, directly contradicting the reference, which clarifies that systemic therapy is appropriate regardless of metastatic status. This is a major inaccuracy that could mislead clinical decision-making."
  },
  "61": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes standard surveillance, and correctly states that PET/CT is reserved for suspicious findings, with no inaccuracies or omissions."
  },
  "62": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing systemic therapy and appropriately discussing the potential role of local therapies, with no inaccuracies or omissions."
  },
  "63": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant chemotherapy with trastuzumab is \"typically recommended\" and \"indicated\" for T1bN0 tumors, whereas guidelines advise consideration on a case-by-case basis rather than routine use; this is a moderate factual error, though the rest of the content is relevant."
  },
  "64": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly states that routine brain MRI is not indicated, and appropriately describes the recommended surveillance approach; additional explanation about higher-stage disease is accurate and clinically relevant."
  },
  "65": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes immediate initiation of EGFR TKI over completing planned systemic and maintenance therapy, missing the key clinical fact that ongoing therapy is prioritized even after discovering an actionable mutation mid-course; it also contains some relevant background but includes a moderate factual error regarding treatment sequencing."
  },
  "66": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that adjuvant radiotherapy is an acceptable alternative when re-excision is not feasible and provides relevant rationale, but it incorrectly assigns a category 2A (instead of 2B) level of evidence, which is a moderate factual error."
  },
  "67": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the treatment sequencing, and provides correct, clinically relevant additional detail without any inaccuracies or omissions."
  },
  "68": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies B cell depletion via anti-CD20 therapy and its effects on antigen presentation and autoantibody production, but it does not explicitly mention \"antibody-dependent cytotoxicity\" as the direct mechanism, omitting a key detail from the reference answer."
  },
  "69": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug and states that its exact mechanism is not fully understood, covering the key fact, but adds speculative mechanisms that are not established, which introduces minor inaccuracy in wording without altering the essential meaning."
  },
  "70": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies P-glycoprotein (P-gp) instead of BCRP as the principal transporter affected by relevant hepatitis C antivirals like velpatasvir, missing the key fact and providing a moderate factual error, though the rest of the content is generally accurate."
  },
  "71": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies IL-1 as the target and provides relevant clinical context, but does not specify the beta isoform (IL-1β) as in the reference answer, which is a minor omission."
  },
  "72": {
    "score": 3.0,
    "explanation": "3: The model answer covers the need for more intensive surveillance with positive margins and mentions typical post-surgical and radiotherapy schedules, but incorrectly states that surveillance should be more intensive after surgery with positive margins than after definitive radiotherapy, which is not supported by guidelines; it also omits the specific recommended imaging intervals for post-radiotherapy patients."
  },
  "73": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining the need for comprehensive profiling and the rationale for excluding ALK and ROS1 rearrangements before EGFR TKI therapy, with no inaccuracies or omissions."
  },
  "74": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies DNA gyrase as the primary target in Streptococcus pneumoniae, omitting topoisomerase IV, which is the main target in this organism; this is a moderate factual error."
  },
  "75": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 enzymes and mentions CYP1A2, but incorrectly emphasizes CYP3A4 as the primary enzyme, which is not supported by the reference answer. There is a minor factual inaccuracy regarding which CYP isoform is primarily induced, but most key facts are covered."
  },
  "76": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly lists relevant mutations, and emphasizes the importance of broad molecular profiling, but omits the explicit statement that it is \"required\" (mandatory) and does not mention the need for adequate tissue or histologic subtype."
  },
  "77": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that chemoradiation is standard regardless of mediastinal lymph node dissection, and provides additional relevant context without inaccuracies or omissions."
  },
  "78": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies fidaxomicin as a possible agent and describes its general mechanism (inhibition of RNA polymerase), but it does not address metronidazole, which is the drug referenced in the question and reference answer; thus, it misses the key fact that the precise mechanism of metronidazole in this context is unclear."
  },
  "79": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) enzymes as the molecular target and explains their role, but does not specify COX-2 (Prostaglandin G/H Synthase 2) as required by the reference answer, resulting in a moderate omission."
  },
  "80": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states the need for more frequent surveillance, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "81": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly prioritizing radiotherapy for symptomatic or high-risk lesions and explaining the role of bisphosphonates/denosumab in reducing skeletal-related events, with no inaccuracies or omissions."
  },
  "82": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies muscarinic receptor activation as the primary mechanism, rather than cholinesterase inhibition, and misattributes pilocarpine as the drug used, missing the key fact from the reference answer."
  },
  "83": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that the exact molecular mechanism is not fully elucidated and identifies the agent as povidone-iodine, but it adds speculative mechanisms (disrupting cell walls, precipitating proteins) that go beyond the reference's \"unknown\" and may imply more certainty than warranted, constituting a minor inaccuracy."
  },
  "84": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, accurately states that routine FDG-PET/CT or brain MRI is not indicated without symptoms or suspicious CT findings, and correctly describes standard surveillance; no inaccuracies or omissions."
  },
  "85": {
    "score": 3.0,
    "explanation": "3: The model answer covers the general mechanism of enzyme inhibition and correctly identifies antiparasitic agents, but it overemphasizes the lack of pharmacological treatment for Guinea worm disease, which is extraneous to the question. It does not clearly state \"enzyme inhibitors\" as the pharmacological class, leading to a minor omission in directly answering the question."
  },
  "86": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies tumor size >5 cm as an indication for chest wall radiotherapy and notes that negative nodes do not preclude this, but it contains inaccuracies (misclassifies T2 as >5 cm, which is actually T3) and some redundant explanations, and does not clearly state that radiotherapy is recommended regardless of preoperative systemic therapy."
  },
  "87": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug class as IL-1 inhibitors, explains the mechanism, and provides a relevant example (Anakinra) without inaccuracies or omissions."
  },
  "88": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains SABR's advantages in this context, and adds relevant, correct details about its precision and the importance of multidisciplinary evaluation, with no inaccuracies or omissions."
  },
  "89": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies insulin and its receptor, but incorrectly states that GLUT4 is the direct molecular target activated by the medication, rather than the insulin receptor itself. This represents a moderate factual inaccuracy, though the rest of the explanation is relevant and accurate."
  },
  "90": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about the rationale and patient selection, and contains no inaccuracies or omissions."
  },
  "91": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that local treatment is warranted prior to systemic therapy in asymptomatic patients, which is not standard practice and omits the key fact that systemic therapy is typically prioritized; however, it does discuss relevant treatment options and considerations, covering some key facts."
  },
  "92": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the agent and its mechanism (antioxidant effect via glutathione replenishment and ROS neutralization), and provides clinically relevant explanation with no inaccuracies or omissions."
  },
  "93": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts, correctly identifies the mechanism as inhibition of nucleic acid (purine) synthesis, and provides relevant examples and explanation without inaccuracies or omissions."
  },
  "94": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies anti-VEGF agents and their mechanism but does not explicitly name \"Biological Response Modifiers\" as the class, missing the key terminology from the reference answer. The mechanistic explanation is accurate and relevant, but the primary classification is not directly addressed."
  },
  "95": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that same-lobe nodules upstage to IIIB and prioritize systemic therapy, which is inaccurate; it misses that curative-intent perioperative therapy remains appropriate, and systemic therapy for metastatic disease is not indicated unless nodules are in a different lobe or lung."
  },
  "96": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for treatment decisions, and adds relevant, correct details about N2 disease and possible reconsideration of surgery after induction therapy, with no inaccuracies or omissions."
  },
  "97": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies ALK1 as the primary target instead of ACVR2A, which is a moderate factual error, though the rest of the explanation is relevant and not unsafe."
  },
  "98": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately identifies the pharmacologic class, mechanism, and clinical relevance, with additional correct and relevant details about clindamycin and bacterial vaginosis."
  },
  "99": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant considerations but omits the key clinical fact that standard practice is to recommend best supportive care only in this scenario; it overemphasizes possible systemic therapy options, which is not supported by guidelines for ECOG 3 patients, leading to a moderate factual inaccuracy."
  },
  "100": {
    "score": 4.0,
    "explanation": "4: The model answer correctly describes antibody-mediated neutralization and opsonization, covering most key facts, but does not explicitly mention Fc receptor engagement or immune modulation, which is a minor omission."
  },
  "101": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that surgery can be considered but that induction systemic therapy is often advocated; it emphasizes multidisciplinary decision-making and relevant clinical considerations. However, it does not clearly state that induction systemic therapy is generally preferred, which is a minor omission."
  },
  "102": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the therapy as recombinant clotting factor replacement and explains its role in the coagulation cascade, but it does not explicitly identify the general pharmacological class as \"enzyme activators,\" missing the key terminology required by the question."
  },
  "103": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the protective barrier function (cytoprotection) and explains the mechanism, but does not explicitly use the term \"demulcent activity\" as in the reference; otherwise, it covers all key facts with no clinically significant omissions."
  },
  "104": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale for more frequent imaging, and adds relevant, accurate details without any inaccuracies or omissions."
  },
  "105": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class as TNF inhibitors/blockers and accurately describes their mechanism, but it omits the broader class term \"Biological Response Modifiers\" used in the reference answer."
  },
  "106": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug, its known binding site, and acknowledges that the full mechanism is not completely understood, matching the reference. However, it provides additional mechanistic details (e.g., decreased neurotransmitter release) that, while accurate, go slightly beyond the reference's emphasis on the incompletely characterized nature, representing a minor wording inaccuracy."
  },
  "107": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly addresses eligibility for BRAF-targeted therapy regardless of prior radiotherapy or palliative care, and adds relevant, accurate details about specific agents and clinical considerations."
  },
  "108": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing brain metastasis treatment and providing a clear rationale without inaccuracies or omissions."
  },
  "109": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly stating that the surveillance protocol applies regardless of adjuvant radiotherapy, and provides relevant context. However, the final sentence introduces minor ambiguity by suggesting possible variation, which is not reflected in the reference answer."
  },
  "110": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about histology/genomics and multidisciplinary considerations, and contains no inaccuracies or omissions."
  },
  "111": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant concepts (staging, typical classification, and treatment implications) but misses the key fact that if lesions are classified as two primaries, both are presumed potentially curable; it also overemphasizes standard metastatic management, which is not the focus of the question, and omits the central point about curative intent."
  },
  "112": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly emphasizing that ER-positivity and nodal status guide endocrine therapy decisions, and does not require features beyond those specified. There is some redundant explanation about invasive potential and risk assessment, but no clinically significant omissions or inaccuracies."
  },
  "113": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for preoperative systemic therapy in both HER2-positive and triple-negative cases, and correctly prioritizes systemic therapy over immediate surgery, with no inaccuracies or omissions."
  },
  "114": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that proceeding with stage III-specific treatment based on imaging alone is generally acceptable, which contradicts the reference's requirement for pathological confirmation; while it discusses MDT input and imaging criteria, it omits the key fact that tissue diagnosis is essential and imaging alone is insufficient, constituting a moderate factual error."
  },
  "115": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies dapsone and its anti-inflammatory effects but omits the key fact that its molecular mechanism involves inhibition of PABA utilization in folate synthesis; it instead emphasizes neutrophil chemotaxis suppression, which is less direct and not the primary molecular mechanism referenced."
  },
  "116": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed, accurate summary of proposed mechanisms for bile acid therapy but does not emphasize that the precise molecular mechanism is unknown, as required by the reference; it covers relevant facts but omits the key point of uncertainty."
  },
  "117": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that adjuvant systemic therapy is not routinely required and observation is appropriate, while also correctly noting that adjuvant therapy may be considered based on individual risk factors; all additional content is factually correct and clinically relevant."
  },
  "118": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the clinical scenario and the use of imiquimod, but incorrectly names TLR7 as the most directly inhibited molecular target, rather than RNA replicase, which is the reference answer. The explanation is otherwise relevant but misses the key fact required."
  },
  "119": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class (tetracyclines), accurately describes the mechanism of action, and contains no inaccuracies or omissions; all key facts from the reference are included."
  },
  "120": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies relevant high-risk features, and appropriately states that adjuvant therapy is not standard for all; additional content is accurate and clinically relevant."
  },
  "121": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the importance of pathological confirmation and multidisciplinary discussion, but it incorrectly suggests that empiric treatment based on imaging alone may be acceptable without exhausting all alternative diagnostic strategies, which is a moderate omission compared to the reference."
  },
  "122": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, acknowledging the rarity of ROS1 rearrangements in squamous cell carcinoma and the need for clinical judgment, but it overstates the routine use of ROS1 inhibitors regardless of histology, missing that squamous histology is generally an exclusion criterion per guidelines."
  },
  "123": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as inhibition of bacterial enzymes (transpeptidases) and accurately names the beta-lactam class, but it does not explicitly use the general term \"enzyme inhibitors\" as in the reference; otherwise, all key facts are present."
  },
  "124": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the drug class as tyrosine kinase inhibitors, and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "125": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes vitamin A’s role in the visual cycle and epithelial maintenance but omits the key reference mechanism—antioxidant (free radical scavenging) activity—thus missing the specific molecular protection asked for."
  },
  "126": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the exact molecular target responsible for amiodarone’s therapeutic effect in atrial fibrillation is not fully elucidated, matching the reference answer. It provides additional, accurate, and relevant information about amiodarone’s classification and actions, with only a minor deviation in focus by specifying the drug and its known channel effects, but no clinically significant omissions or inaccuracies."
  },
  "127": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class (beta-lactam antibiotics) and mechanism (inhibition of transpeptidase enzymes), but does not explicitly state the broader class \"enzyme inhibitors\" as in the reference; otherwise, all key facts are present."
  },
  "128": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting durvalumab as standard and the uncertainty regarding osimertinib in this setting, but it omits that osimertinib is preferred for EGFR-mutant cases based on superior efficacy, and does not clearly prioritize osimertinib over durvalumab as the reference does."
  },
  "129": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that stage II NSCLC requires less frequent surveillance than stage III, which contradicts guidelines recommending the same surveillance schedule for both. It covers some general principles but omits the key fact that surveillance frequency is the same, and contains a moderate factual error."
  },
  "130": {
    "score": 5.0,
    "explanation": "5: Fully covers the key fact of protein synthesis inhibition, accurately explains the mechanism, and provides a relevant example (ciclopirox) without any inaccuracies or irrelevant content."
  },
  "131": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference by explicitly stating that the precise mechanism is not fully understood, while also providing accurate, clinically relevant details about Baclofen’s known pharmacological action. There are no inaccuracies or omissions."
  },
  "132": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies inhibition of topoisomerase IV as a primary mechanism and provides accurate, relevant details about fluoroquinolones and their targets, but it does not explicitly single out topoisomerase IV as the main mechanism for chromosome segregation, slightly diluting the focus compared to the reference."
  },
  "133": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that surveillance should be more frequent than annually and gives an appropriate rationale, but it specifies \"every 6 months\" rather than the full \"every 3–6 months\" range, omitting the possibility of more frequent (every 3 months) imaging as per guidelines. All other key facts are present."
  },
  "134": {
    "score": 4.0,
    "explanation": "4: The answer correctly identifies PDE5 as the molecular target and explains its role in cGMP hydrolysis and the effects of its inhibition, covering nearly all key facts. There is a minor inaccuracy in implying that NSAIDs commonly target PDE5 in osteoarthritis, but this does not significantly alter the core explanation."
  },
  "135": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including prioritizing concurrent chemoradiation, rationale for downstaging and addressing micrometastatic disease, and the role of multidisciplinary evaluation; there are no inaccuracies or omissions."
  },
  "136": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and provides relevant details about standard regimens without any inaccuracies or omissions."
  },
  "137": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly identifies 5-HT3 antagonism rather than dopamine antagonism as the key mechanism, which is a major factual error and misses the core clinical fact from the reference."
  },
  "138": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies EGFR instead of HER2/neu as the direct molecular target, and introduces imiquimod/5-FU, which are not receptor tyrosine kinase inhibitors, constituting a moderate factual error and some irrelevant content."
  },
  "139": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies ACTH as the synthetic analog, explains its action in stimulating adrenal steroidogenesis, and details the anti-inflammatory effects of increased cortisol. However, it does not explicitly state \"pituitary hormone receptor agonism\" or \"activation of the ACTH receptor,\" which is the precise mechanism asked for, representing a minor omission."
  },
  "140": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that current evidence supports completing planned systemic therapy (including maintenance) before starting targeted therapy, unless clinically indicated otherwise, and instead incorrectly recommends immediate switching, which is a moderate factual error."
  },
  "141": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies TNF-alpha as the molecular target instead of interleukin-1 beta, which is the key fact in the reference answer; while the rest of the explanation is relevant, this represents a moderate factual error."
  },
  "142": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class as antimetabolites and accurately describes the mechanism of ribonucleotide reductase inhibition, but it does not explicitly use the broader class term \"nucleic acid synthesis inhibitors\" as in the reference; otherwise, all key facts are covered."
  },
  "143": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the limited benefit of durvalumab in EGFR-mutant NSCLC and the rationale for considering osimertinib, but it equivocates on the preferred agent and omits the increased risk of adverse events with immunotherapy in this subgroup, leading to some ambiguity and a minor omission."
  },
  "144": {
    "score": 2.0,
    "explanation": "2: The model answer does not mention thyroid hormone receptor agonists, the key fact in the reference, and instead focuses on FXR and PPAR agonists, which is a moderate factual error/omission. The mechanistic discussion is partially relevant but misses the specific class asked for."
  },
  "145": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies \"Beta-lactams\" as the pharmacological class and accurately describes their mechanism, but it omits the broader class \"Enzyme Inhibitors\" as in the reference; this is a minor omission."
  },
  "146": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly cites the indication for ado-trastuzumab emtansine in the specified scenario, and provides relevant supporting evidence without inaccuracies or omissions."
  },
  "147": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that SRS is generally preferred even in the presence of mild neurological symptoms, whereas the reference specifies that surgical resection is preferred when symptoms are present. While the answer provides relevant details, it omits the key fact that mild symptoms favor surgery over SRS, constituting a moderate factual error."
  },
  "148": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies nucleoside analogs, explains their phosphorylation and incorporation into viral DNA, and notes inhibition of DNA polymerase, but does not explicitly use the term \"DNA polymerase inhibitors\" as in the reference; otherwise, it covers all key facts."
  },
  "149": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the rationale for treating the lesions as separate primaries if potentially curable, and adds relevant, correct details about multidisciplinary evaluation and molecular profiling without introducing inaccuracies."
  },
  "150": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that pathologic confirmation of the metastatic site is recommended before local therapy and instead suggests it is reasonable to proceed without it, which is a moderate factual error; while it discusses relevant considerations, it does not align with current guidelines."
  },
  "151": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing osimertinib over durvalumab in EGFR-mutated NSCLC and providing relevant, accurate rationale without any inaccuracies or omissions."
  },
  "152": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the drug class as calcium channel blockers rather than adrenergic alpha-antagonists, which is a moderate factual error, though the described mechanism is accurate for CCBs and not unsafe."
  },
  "153": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly prioritizing immediate SVC stenting for symptomatic relief before starting chemoradiation, with no inaccuracies or omissions."
  },
  "154": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies dopamine agonists as directly stimulating dopamine receptors but spends most of the response discussing standard treatments (dopamine antagonists) and questions the scenario, leading to partial coverage and some irrelevant content; it does not fully align with the reference answer."
  },
  "155": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that similar surveillance schedules are appropriate, omitting the key fact that closer (every 3–6 months) surveillance is recommended after definitive radiotherapy; this is a moderate factual error and misses the main distinction highlighted in the reference."
  },
  "156": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the primary target and explains its role in prostaglandin synthesis and dysmenorrhea, but does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference, which is a minor omission."
  },
  "157": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly stating that surveillance for oligometastatic stage IV NSCLC generally mirrors that of stage III, with similar frequency and imaging modality. However, it omits the precise surveillance intervals and does not explicitly state that there is no distinction in recommended protocols, introducing some ambiguity and minor omissions."
  },
  "158": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly emphasizes the importance of broad molecular profiling regardless of smoking status or metastasis location, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "159": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the molecular target and provides accurate, relevant explanation without errors or omissions."
  },
  "160": {
    "score": 2.0,
    "explanation": "2: The model answer covers the EGFR mutation as an indication for EGFR TKI but incorrectly overemphasizes the impact of a concurrent KRAS mutation, suggesting EGFR TKIs may not be appropriate and recommending alternative therapies, which is a moderate factual error and a key omission compared to the reference answer."
  },
  "161": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the supplement and its role in cartilage metabolism, but it focuses on \"substrate provision for biosynthesis\" rather than the broader \"biological macromolecular activity\" described in the reference, missing the key categorical mechanism."
  },
  "162": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, correctly identifies targeted therapy as preferred, names appropriate agents, and provides relevant rationale without inaccuracies or omissions."
  },
  "163": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that amivantamab-vmjw plus lazertinib is not appropriate first-line therapy for EGFR exon 19 deletion, omitting that this combination is now an approved first-line option. It also incorrectly restricts amivantamab-vmjw to post-TKI or exon 20 insertion settings, which is outdated, but does mention standard TKI therapy and does not provide unsafe advice."
  },
  "164": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly states that immunotherapy alone is not recommended, prioritizes chemotherapy, specifies the standard platinum-based regimen, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "165": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies bismuth subsalicylate, its mucosal coating action, and its antimicrobial effects, covering over 90% of the key facts. However, it does not explicitly mention modulation of gastric acidity (acid-base activity) as in the reference, which is a minor omission."
  },
  "166": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PDGFR instead of VEGFR as the receptor whose inhibition directly reduces fibroblast activity, which is a moderate factual error; while the explanation is otherwise relevant, this key inaccuracy lowers the score."
  },
  "167": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that chemotherapy is likely indicated for a recurrence score of 25, whereas current guidelines recommend chemotherapy only for scores ≥26; this is a moderate factual error, though the rest of the answer is generally relevant."
  },
  "168": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies COX-2 as the primary target, whereas the reference specifies COX-1. While the explanation is otherwise accurate and relevant, this represents a moderate factual error regarding the specific molecular target."
  },
  "169": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathological confirmation before treatment, and correctly describes the rationale and methods for confirmation without any inaccuracies or omissions."
  },
  "170": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that non-contrast CT is sufficient in this scenario, and provides additional relevant explanation without inaccuracies or omissions."
  },
  "171": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly identifies dual HER2 blockade as preferred in high-risk/node-positive cases, and discusses risk stratification and individualized decision-making. However, it omits explicitly stating that trastuzumab without pertuzumab is reserved for contraindications or intolerance, which is a minor omission."
  },
  "172": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the IL-12/IL-23 receptor complex instead of the interferon alpha receptor complex, which is a moderate factual error; while it mentions JAK-STAT signaling and immune modulation, it misses the key target specified in the reference."
  },
  "173": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the appropriateness of local therapy in oligometastatic NSCLC, and adds relevant, correct details about treatment modalities and decision factors without any inaccuracies or omissions."
  },
  "174": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately prioritizing BRAF-targeted therapy and providing relevant, correct additional details about specific agents and rationale, with no inaccuracies or omissions."
  },
  "175": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly suggests that immediate transition to afatinib is appropriate and does not prioritize completion of the current systemic regimen, missing the key standard-of-care sequence. While it provides correct information about mutation sensitivity and drug selection, it omits the guideline-based recommendation to finish initial therapy, which is a moderate factual omission."
  },
  "176": {
    "score": 3.0,
    "explanation": "3: The model answer correctly emphasizes the importance of brain imaging and recommends non-contrast MRI if contrast is contraindicated, but incorrectly states that non-contrast MRI is \"essential\" (rather than optional/alternative) and omits that brain CT is an acceptable alternative if MRI is unavailable, missing some nuance from the reference."
  },
  "177": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and explains the mechanism and clinical relevance, but does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference; this is a minor omission since aspirin inhibits both COX-1 and COX-2."
  },
  "178": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that broad molecular profiling is still recommended in advanced squamous NSCLC to identify rare actionable mutations, and instead incorrectly downplays its routine use, suggesting it is only for select cases or investigational settings. While it provides some correct background, this represents a moderate factual omission and misrepresents current guidelines."
  },
  "179": {
    "score": 5.0,
    "explanation": "5: The model answer accurately explains that a separate nodule in the same lobe is T3 and that T3, N0, M0 corresponds to stage IIB, matching all key clinical facts in the reference without omissions or inaccuracies."
  },
  "180": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that 21-gene RT-PCR testing is recommended for ER-positive, HER2-negative, node-negative tumors >0.5 cm, and appropriately applies this to the scenario. There is a minor wording inaccuracy regarding the strength of the recommendation (\"could still be considered\" vs. \"strongly recommended\"), but no clinically significant omissions or errors."
  },
  "181": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies phospholipase A2 inhibitors rather than lipoxygenase inhibitors as most directly responsible, which is a moderate factual error, though the mechanistic explanation is otherwise accurate."
  },
  "182": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that neoadjuvant therapy is justified in cT1c, cN0, HER2-positive cases and not limited to cT2 or node-positive disease, with additional relevant and accurate explanations."
  },
  "183": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing the necessity of ruling out distant metastases with appropriate imaging before perioperative therapy, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "184": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the mechanism (prevention of acetylcholine release) and mentions botulinum toxin, but the drug class given (\"neuromuscular blocking agents\") is less precise than \"acetylcholine release inhibitors\" and could be misleading, as most neuromuscular blockers act postsynaptically; this is a minor inaccuracy in terminology."
  },
  "185": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise molecular mechanism of coal tar is not fully established and provides additional, factually accurate and clinically relevant information about its possible actions; however, it slightly overstates the current understanding by listing proposed mechanisms, which are not definitively established, but this does not alter the core meaning."
  },
  "186": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the exact molecular mechanism is not fully detailed and acknowledges the uncertainty, but it provides additional mechanistic speculation (e.g., inhibition of fatty acid synthesis, anti-inflammatory effects) that, while plausible, is not established for this clinical context; this constitutes a minor inaccuracy in wording but does not alter the essential meaning."
  },
  "187": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies VEGF as the primary target and explains the anti-angiogenic mechanism, but does not specify the VEGF-A isoform as in the reference; this is a minor omission."
  },
  "188": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism (inhibition of PBPs, preventing peptidoglycan cross-linking) and identifies the drug class, but does not explicitly use the term \"transpeptidase inhibitors,\" which is the precise class referenced; this is a minor wording inaccuracy."
  },
  "189": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately noting that broad molecular profiling is prioritized in nonsquamous NSCLC but should still be considered in squamous cell carcinoma for never-smokers or younger patients; there are no inaccuracies or omissions."
  },
  "190": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies MCTs and their unique absorption pathway, but it overemphasizes fatty acid transport proteins and enzymes rather than the structural membrane components (as per the reference), and introduces some minor inaccuracies regarding the necessity of transport proteins, resulting in partial coverage of key facts."
  },
  "191": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism (truncated AR variant lacking ligand-binding domain and its role in resistance) but incorrectly names the specific variant as AR-V7 instead of AR-V3, which is a moderate factual error."
  },
  "192": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies tubulin as the principal target, explains the clinical context (FMF), mechanism of colchicine, and its relevance; all extra details are accurate and clinically relevant."
  },
  "193": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly stating that concurrent chemoradiation is appropriate and that re-resection is not mandatory, but it slightly overemphasizes re-resection as an option, which is not required per guidelines; otherwise, content is accurate and relevant."
  },
  "194": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, correctly stating that omission of further axillary surgery is permissible with planned axillary radiotherapy after mastectomy or breast-conserving surgery, and provides relevant, factually correct additional context."
  },
  "195": {
    "score": 3.0,
    "explanation": "3: Covers the majority of key facts, mentioning reduction of oxidative stress and improved oxygen delivery, but does not specifically identify free radical scavenging as the molecular mechanism; some minor inaccuracies and lack of focus on the precise reference mechanism."
  },
  "196": {
    "score": 3.0,
    "explanation": "3: The answer identifies DNA gyrase instead of topoisomerase IV as the principal target for decatenation, which is a moderate factual inaccuracy, though it correctly discusses fluoroquinolones and their general mechanism; about 70-89% of key facts are covered."
  },
  "197": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that the principal mechanism is antioxidant (free radical scavenging) activity, instead focusing on epithelial differentiation, which is secondary; this is a moderate omission."
  },
  "198": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism of bile acid sequestrants, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "199": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that surveillance frequency is the same after radiotherapy and surgery, missing the key fact that post-radiotherapy surveillance should be more intensive; this is a major inaccuracy."
  },
  "200": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, emphasizing the necessity of preoperative PFTs in patients with COPD, and provides relevant rationale. However, the statement that \"surgery might ultimately proceed based on clinical judgment\" introduces minor ambiguity, slightly weakening the categorical recommendation found in the reference."
  },
  "201": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine brain MRI is not indicated, explains the rationale, and provides relevant additional context without inaccuracies or omissions."
  },
  "202": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the need for detailed functional assessment and referencing specific pulmonary function thresholds, but it incorrectly suggests that standard therapy can proceed without modification solely due to moderate restrictive impairment, which contradicts the reference's emphasis that such impairment may require modification or contraindicate surgery."
  },
  "203": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that histological subtype does not affect eligibility, omitting the key fact that metaplastic carcinoma is excluded, which is a moderate factual error; it otherwise covers the clinical scenario and rationale."
  },
  "204": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant facts but incorrectly suggests that ALND can be avoided if only the marked node remains positive after systemic therapy, which contradicts current standard guidelines; this represents a moderate factual error and omits the key point that ALND is generally mandated when residual nodal disease is present."
  },
  "205": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains the mechanism, but it does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference answer, and incorrectly emphasizes COX-2 as the main form, which is less relevant in primary dysmenorrhea."
  },
  "206": {
    "score": 3.0,
    "explanation": "3: The model answer explains the physical and chemical mechanisms of sunscreens accurately but fails to explicitly name the overarching mechanism as \"physiochemical activity,\" which is the key fact in the reference answer. The explanation is otherwise correct and relevant."
  },
  "207": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the necessity of confirming M0 status with brain MRI and FDG-PET/CT, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "208": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies sulfonamides as PABA analogs and thoroughly explains their mechanism, but it does not explicitly use the term \"PABA inhibitors\" as in the reference; otherwise, all key facts are present and accurate."
  },
  "209": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key facts, correctly describing niacin’s effects on lipid metabolism and vasodilation, and mentions enzyme inhibition, but does not explicitly state \"enzyme interactions\" as the general pharmacological mechanism, and includes some mechanistic detail (GPR109A) that, while accurate, is not central to the reference answer."
  },
  "210": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid (cytoplasmic) receptor, accurately describes its intracellular location and mechanism, and covers all key clinical facts from the reference without any inaccuracies or omissions."
  },
  "211": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that surgery is not appropriate due to both stage and poor lung function, and appropriately recommends non-surgical therapies. Additional content about chemoradiation and systemic therapy is accurate and clinically relevant."
  },
  "212": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies rasburicase and accurately describes its mechanism as enzymatic conversion of uric acid to allantoin, but it does not explicitly use the term \"enzyme activation\" or \"enzyme activator\" as in the reference, which is a minor wording inaccuracy."
  },
  "213": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that durvalumab is typically not used in patients with EGFR exon 19 or L858R mutations, which is a moderate factual error, as durvalumab is indicated regardless of EGFR status; it also overemphasizes targeted therapy in this setting, missing the key fact that durvalumab is not excluded by these mutations."
  },
  "214": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that broad molecular profiling is not routinely recommended in typical squamous NSCLC but should be considered in never/light smokers or if histology is uncertain; it also appropriately mentions PD-L1 testing. There is a minor omission in not explicitly stating that molecular testing should not be omitted solely based on squamous histology, but overall content is accurate and clinically relevant."
  },
  "215": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the need for additional therapy after R2 resection, and provides relevant, accurate details about treatment options without any inaccuracies or omissions."
  },
  "216": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that surveillance intervals are generally the same for radiotherapy and surgery, omitting the recommendation for more intensive follow-up after radiotherapy and missing key details about the increased frequency of imaging in the first 3 years; this is a moderate factual omission."
  },
  "217": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug and its mechanism, but gives \"anticoagulants\" as the pharmacological class rather than the more precise \"enzyme activators\" as in the reference; while most key facts are covered, the main classification is not fully aligned."
  },
  "218": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the drug class and mechanism (nicotinic acetylcholine receptor agonists/pyrantel pamoate) instead of cholinesterase inhibitors, which is the reference answer; while the mechanism described is accurate for pyrantel pamoate, it does not match the reference, constituting a moderate factual error."
  },
  "219": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme, which covers the essential clinical fact, but does not specify COX-1 as in the reference answer; this is a minor omission since many NSAIDs inhibit both COX-1 and COX-2, but the reference specifically names COX-1."
  },
  "220": {
    "score": 2.0,
    "explanation": "2: The model answer misses the key fact that if definitive local therapy is not possible, surgery (as a form of definitive local therapy) is inherently excluded; instead, it incorrectly suggests surgery may still be considered, which is a moderate factual error. It does provide some relevant context but fails to align with the reference's core clinical reasoning."
  },
  "221": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation about the rationale and methods for ovarian suppression, and contains no inaccuracies or omissions."
  },
  "222": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation, and provides relevant, correct additional detail without any inaccuracies or omissions."
  },
  "223": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing zinc's role as a metalloenzyme cofactor and its essential functions in tissue repair, with no inaccuracies or omissions."
  },
  "224": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the medication as a glucocorticoid and explains its inhibition of phospholipase A2, but it does not name lipoxygenase enzymes as the primary enzyme system responsible for the lipid mediators in question, missing the key fact from the reference answer."
  },
  "225": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states the preference for MET-targeted therapy (crizotinib) over chemotherapy, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "226": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the 5-HT1B receptor as the direct molecular target, matching the reference answer with no omissions or inaccuracies."
  },
  "227": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine brain MRI is not indicated in asymptomatic patients, and appropriately notes that MRI is reserved for symptomatic or high-risk cases. There are no inaccuracies or omissions."
  },
  "228": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the need for pathologic confirmation, discusses the limitations of FDG-PET/CT, and appropriately describes the implications for treatment planning without any inaccuracies or omissions."
  },
  "229": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that brain MRI is not standard for stage II and is only indicated for stage IIIA or higher, omitting the key fact that brain MRI is recommended (though not strictly mandatory) for stage II. This is a moderate factual omission that could impact clinical decision-making."
  },
  "230": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on vitamin A’s role in epithelial differentiation and mucin production, omitting the key fact that retinyl acetate’s primary mechanism here is antioxidant (free radical scavenging) activity; it provides relevant but not the main mechanism, constituting a moderate omission."
  },
  "231": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, noting the limited benefit of durvalumab in EGFR-mutant NSCLC and the preference for targeted therapy, but it equivocates on durvalumab's appropriateness and does not clearly state that osimertinib is now preferred, missing the definitive recommendation in the reference."
  },
  "232": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cytochrome P450 enzymes as the relevant class and explains their role in albendazole metabolism, but it omits the specific CYP1A subfamily mentioned in the reference answer, which is a minor omission."
  },
  "233": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the thrombopoietin receptor as the primary molecular complex, rather than the interferon alpha receptor complex specified in the reference. While it provides relevant mechanistic detail, this represents a moderate factual error and covers less than 70% of the key facts."
  },
  "234": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant, correct details about management options and multidisciplinary discussion, with no inaccuracies or omissions."
  },
  "235": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that the drug acts via ion channel interactions (specifically NMDA receptor blockade) and increases dopamine release, but it does not explicitly state \"ion channel interactions\" as the primary pharmacological interaction, instead focusing on indirect dopamine agonism, which is less precise for this question."
  },
  "236": {
    "score": 3.0,
    "explanation": "3: The model answer covers the uncertainty of the mechanism and correctly describes general corticosteroid actions, but it does not explicitly state that the cellular or molecular interaction is unknown, as required by the reference; instead, it speculates on possible mechanisms, which is more than the reference supports."
  },
  "237": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing the need to consider pulmonary function before radiotherapy and the appropriateness of SVC stenting regardless of pulmonary status. There is a minor wording inaccuracy suggesting that radiotherapy may still be considered in emergencies, but it does not alter the core clinical message."
  },
  "238": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug class (polyene antifungals) and its mechanism (binding to ergosterol or similar sterols to disrupt membrane integrity), but does not explicitly state \"inhibition of ergosterol synthesis\" as required; instead, it focuses on membrane disruption, which is related but not the specific pathway asked."
  },
  "239": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly states that chest CT is sufficient for routine surveillance, and that FDG-PET/CT is reserved for suspected recurrence or equivocal findings; there are no inaccuracies or omissions."
  },
  "240": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PDE4 (cAMP-specific) instead of the reference's cGMP-specific phosphodiesterase, and also incorrectly associates celecoxib with PDE4 inhibition; these are moderate factual errors, though the answer is otherwise relevant."
  },
  "241": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as inhibition of nucleic acid synthesis via folate synthesis inhibitors and provides relevant examples, but it omits the broader class term \"nucleic acid synthesis inhibitors\" used in the reference, which is a minor wording inaccuracy."
  },
  "242": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the assumption regarding absence of distant metastases, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "243": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the general drug class (fluoroquinolones) and their mechanism but incorrectly names DNA gyrase as the most direct target, whereas topoisomerase IV is the primary target in gram-positive organisms like those commonly causing otitis media; this is a moderate factual error."
  },
  "244": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly stating that immunotherapy is generally prioritized first-line in high PD-L1 cases and that KRAS G12C inhibitors are effective, but it inaccurately suggests targeted therapy could be considered first-line, which is not current standard practice; this is a moderate factual inaccuracy."
  },
  "245": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies SNRIs and explains their mechanism, but the reference specifically asks for \"serotonin uptake inhibitors,\" not SNRIs or SNRIs' dual action; thus, the answer partially diverges from the reference and does not directly match the required class."
  },
  "246": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that both approaches are acceptable but chemoradiation is generally preferred due to the R1 margin; additional content is accurate, relevant, and does not introduce errors or omissions."
  },
  "247": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the agent as non-absorbed and acting within the GI tract, and explains its osmotic effect, which is relevant for some agents like PEG. However, it does not mention \"stool bulking activity\" as the key property, missing the specific mechanism highlighted in the reference answer."
  },
  "248": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies adenosine and its action on A1 adenosine receptors but incorrectly states that methylxanthines (antagonists) share the same primary molecular target as agonists, which is not accurate per the question's intent; this constitutes a moderate factual error."
  },
  "249": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, noting that molecular testing may be considered in non-smokers with squamous histology, but incorrectly states that routine testing is generally not performed and implies it is not standard, which is a moderate factual inaccuracy given current guidelines recommend broad testing if tissue is available."
  },
  "250": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the possibility of omitting ALND after preoperative therapy if only one sentinel node is positive, and references relevant studies and evolving guidelines. However, it omits the critical requirement that adjuvant radiotherapy should be planned to cover the undissected axilla, which is essential for safe omission of ALND, and lacks explicit mention of the importance of marker placement and its role in targeted axillary dissection."
  },
  "251": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds only correct and clinically relevant details, and contains no inaccuracies or omissions."
  },
  "252": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies amantadine, its NMDA receptor antagonism, and mentions dopaminergic modulation, but does not explicitly state that amantadine enhances dopamine release, which is a key fact in the reference answer."
  },
  "253": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies PABA inhibition in folate synthesis as Dapsone's mechanism, but overemphasizes its anti-inflammatory effects as the primary therapeutic benefit, which is not the focus of the question. There is some extraneous but accurate information, but the key mechanism is not clearly stated as the main answer."
  },
  "254": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug class (JAK inhibitor) and mechanism but does not specify JAK1, the precise molecular target given in the reference; it instead refers generally to the Janus kinase family, which is less specific."
  },
  "255": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting the potential for two primary tumors and the implications for curative management, but introduces some ambiguity and conditional language rather than clearly stating that such cases should be managed as synchronous primaries if resectable, as in the reference."
  },
  "256": {
    "score": 3.0,
    "explanation": "3: The model answer covers the uncertainty of the precise mechanism and acknowledges ongoing study, but it spends excessive space speculating about drug classes and provides detailed mechanisms for several agents, which is not required. It ultimately conveys that the exact cellular interaction is unknown, but with some minor inaccuracies and unnecessary elaboration."
  },
  "257": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately explains the rationale, and contains no inaccuracies or omissions."
  },
  "258": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies that the precise mechanism is not fully elucidated and provides relevant, factually accurate context about tafenoquine’s possible actions, with only a minor addition that does not alter the core meaning."
  },
  "259": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains its role in prostaglandin synthesis and symptom relief, but does not specifically name COX-1 (prostaglandin G/H synthase 1) as the primary enzyme, which is a minor omission."
  },
  "260": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies DNA gyrase as the primary target for chromosome separation, whereas topoisomerase IV is the key enzyme for this function; this is a moderate factual error, though the rest of the explanation is relevant."
  },
  "261": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the rationale for thoracic chemoradiation in oligoprogressive disease, and adds relevant, correct considerations without any inaccuracies or omissions."
  },
  "262": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that observation alone is not acceptable, directly contradicting the reference answer, which recognizes observation as an option. While the model provides relevant details about adjuvant therapy, this moderate factual error significantly impacts the score."
  },
  "263": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts from the reference, including the prioritization of local ablative therapy in select oligometastatic NSCLC patients and the continued importance of systemic therapy in higher burden or unfavorable cases. It adds relevant detail about patient selection and multidisciplinary decision-making, but slightly overemphasizes delaying systemic therapy and does not explicitly state that systemic therapy is the mainstay for higher metastatic burden, which is a minor omission."
  },
  "264": {
    "score": 2.0,
    "explanation": "2: The model answer identifies phosphodiesterase inhibition but incorrectly specifies PDE4 instead of cGMP-specific phosphodiesterase, and does not directly name cGMP-specific 3',5'-cyclic phosphodiesterase; this is a moderate factual error."
  },
  "265": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for concurrent chemoradiation, and provides relevant additional details without any inaccuracies or omissions."
  },
  "266": {
    "score": 2.0,
    "explanation": "2: The model answer misidentifies the drug as cilostazol rather than papaverine, and provides an incorrect mechanism of action, missing the key fact that papaverine’s precise mechanism is unknown; while it mentions uncertainty, the explanation is mostly irrelevant to the reference."
  },
  "267": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism of interferons and partially relates it to NRTIs, which also inhibit viral genome replication, but does not specifically mention RNA replicase inhibitors as in the reference. The answer covers most key facts but lacks precision in matching the reference class."
  },
  "268": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly stating that management as two primaries is considered only if both lesions are potentially curable, and adds relevant details about evaluation. However, it omits the explicit statement that if not both are curable, the default is systemic therapy for metastatic disease."
  },
  "269": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference, accurately states that routine PET/CT and brain MRI are not recommended without suspicion, and correctly describes standard follow-up; extra content is relevant and guideline-based."
  },
  "270": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that nintedanib inhibits multiple receptor families, including FGF receptors, but incorrectly states that the principal molecular target is the PDGF receptor family rather than the fibroblast growth factor receptor family, which is the focus of the question; otherwise, the explanation is accurate and relevant."
  },
  "271": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the importance of confirming receptor status on metastatic lesions due to possible discordance, but it incorrectly states that confirmation is not implicitly required and suggests treatment may proceed based solely on the primary tumor, which is a moderate factual inaccuracy compared to the reference answer."
  },
  "272": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts—identifies human albumin as the agent, explains its role in increasing oncotic pressure, and describes the mechanism of reducing edema; all additional details are accurate and clinically relevant."
  },
  "273": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that management assumes metastatic disease rather than potentially resectable primaries, missing the key clinical nuance in the reference. It covers some relevant facts about M1a and treatment options but omits the critical point that both lesions may be considered for curative resection, which is central to the reference answer."
  },
  "274": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the dependence on prior EGFR TKI exposure, and adds relevant, accurate details about resistance mutations and subsequent management without any inaccuracies or omissions."
  },
  "275": {
    "score": 3.0,
    "explanation": "3: The model answer covers the mechanism of corticosteroids and their effect on leukotriene synthesis, but it does not specifically identify \"lipoxygenase inhibitors\" as the pharmacological class directly responsible for decreasing leukotriene-mediated inflammation, as required by the question."
  },
  "276": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the rationale for broad molecular profiling despite PD-L1 positivity and prior negative results, and adds relevant points about rare mutations and clinical trial eligibility without inaccuracies or omissions."
  },
  "277": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the use of a prostaglandin analog and its action on G-protein-coupled receptors, but focuses on downstream calcium signaling rather than directly stating \"agonism of prostaglandin (EP) receptors,\" which is the key fact required. The explanation is accurate but does not explicitly name the primary mechanism as EP receptor agonism."
  },
  "278": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies IL-1 signaling as the targeted pathway and provides relevant clinical context, but adds detail about NF-κB activation, which, while accurate, is not the most direct answer and could be seen as a minor wording inaccuracy compared to the reference's focus on IL-1 receptor antagonism."
  },
  "279": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that preoperative pulmonary function assessment is mandatory before surgery and explaining its purpose, with no inaccuracies or omissions."
  },
  "280": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies beta-adrenergic agonists and explains their mechanism, but does not specify beta2-agonists as in the reference; however, the explanation is otherwise accurate and clinically relevant."
  },
  "281": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies ACTH and its mechanism, covering nearly all key facts, but does not explicitly state \"pituitary hormone receptor agonists\" as the pharmacological class, which is a minor omission."
  },
  "282": {
    "score": 4.0,
    "explanation": "4: The model answer accurately states that targeted therapy is precluded and chemotherapy is prioritized, and correctly notes the lack of benefit from immunotherapy monotherapy; however, it introduces the possibility of chemo-immunotherapy, which is not directly addressed in the reference and could be seen as a minor deviation in focus, though not clinically incorrect."
  },
  "283": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed mechanism of action for radioactive iodine, focusing on beta radiation-induced DNA damage, which is not supported by the reference answer stating the mechanism is unknown; this constitutes a moderate factual error."
  },
  "284": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly specifies a fixed 6-month interval rather than the recommended 3–6 month range, omitting the option for more frequent surveillance; otherwise, the content is accurate and relevant."
  },
  "285": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies albendazole as a P450 inducer and explains the anticipated reduction in plasma levels of co-administered drugs, but it overstates the range of enzymes induced (CYP2C9 and CYP3A4 are not key for albendazole in this context), which is a minor inaccuracy."
  },
  "286": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly recommends biomarker testing and brain MRI, and explains their relevance. However, it incorrectly classifies a contralateral pulmonary nodule as M1a (it is M1b), which is a minor wording inaccuracy but does not alter the clinical meaning or recommendations."
  },
  "287": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies prostacyclin (IP) receptors as the primary target and accurately explains their hemodynamic effects; no errors or omissions."
  },
  "288": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about specific endocrine options, and contains no inaccuracies or omissions."
  },
  "289": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states the indication for adjuvant systemic therapy regardless of nodal status, and provides relevant, accurate rationale without any inaccuracies or omissions."
  },
  "290": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed, accurate description of the proposed mechanism of chloroquine but does not emphasize that the precise cellular or molecular interaction is unknown, as required by the reference; it covers most key facts but over-specifies the mechanism rather than focusing on the uncertainty."
  },
  "291": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains its role in prostaglandin synthesis, but does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference answer; this is a minor omission."
  },
  "292": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant facts (rarity of co-occurrence, importance of molecular profiling) but omits the key point that use of EGFR TKIs in this context generally presupposes ALK negativity, and incorrectly suggests that concurrent EGFR/ALK alterations do not affect the implication of TKI use, which is a moderate factual error."
  },
  "293": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant trials and concepts but contains a moderate factual error by incorrectly supporting omission of axillary surgery in a patient with three positive SLNs, which exceeds guideline criteria; this is a key clinical point."
  },
  "294": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies serotonin receptor agonism (specifically 5-HT1B/1D) as the primary mechanism, covering the key fact of serotonin receptor modulation, but it focuses on triptans rather than the broader class of agents (e.g., ergot derivatives) that also act as both agonists and antagonists at multiple monoamine receptors, resulting in a minor omission."
  },
  "295": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference, accurately stating that adjuvant radiotherapy is not category 1 standard of care and explaining the lower level of evidence and consensus; additional content is correct and clinically relevant."
  },
  "296": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains why surgery is inappropriate due to both stage and pulmonary function, and correctly describes standard chemoradiotherapy as the preferred approach, with no inaccuracies or omissions."
  },
  "297": {
    "score": 2.0,
    "explanation": "2: The model answer does not mention calcium chelation or reduction of free extracellular calcium, which is the key mechanism in the reference. Instead, it focuses on magnesium's effects on ion channels and early afterdepolarizations, which, while relevant to magnesium's antiarrhythmic properties, do not directly address the specific molecular mechanism asked."
  },
  "298": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the medication as methotrexate rather than aminobenzoate potassium, and provides an extended discussion of methotrexate’s mechanism, which is not relevant to the question. While it acknowledges that the precise mechanism is unclear, the main content is off-target, resulting in a moderate factual error and significant omission of the key fact."
  },
  "299": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, with additional correct and relevant explanation about EGFR mutations and TKI sensitivity; no inaccuracies or omissions."
  },
  "300": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the role of FDG-PET/CT and brain MRI, and appropriately describes the implications for perioperative therapy without any inaccuracies or omissions."
  },
  "301": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining that reduced pulmonary function may contraindicate surgery and that radiotherapy or SABR is preferred in such cases; additional content is correct, relevant, and adds useful clinical context."
  },
  "302": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains its role, but does not specify the COX-2 isoform as in the reference answer; this is a minor omission since NSAIDs inhibit both COX-1 and COX-2, but COX-2 is more relevant to inflammation."
  },
  "303": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that palliative therapy does not exclude close observation and emphasizing individualized decision-making based on symptoms and patient status, with all additional content being clinically relevant and correct."
  },
  "304": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, noting that broad profiling is less routinely indicated in squamous histology but may be considered in select cases; however, it omits the reference's clear recommendation that broad profiling remains indicated due to the possibility of actionable mutations regardless of histology, and its emphasis on individualization may understate current guidelines."
  },
  "305": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the likely medication as valproic acid rather than levetiracetam, and provides details about valproic acid’s mechanism, which is not relevant to the reference answer. While it acknowledges that the exact mechanism is not fully elucidated, the majority of the content is about the wrong drug, constituting a moderate factual error and significant irrelevance."
  },
  "306": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that re-excision is preferred but radiotherapy is an acceptable alternative, and adds relevant detail about decision-making without any inaccuracies or omissions."
  },
  "307": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly noting that adjuvant chemotherapy with trastuzumab and endocrine therapy can be considered for HER2-positive tumors ≤0.5 cm, and emphasizes the individualized, nuanced decision-making process without any inaccuracies or omissions."
  },
  "308": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the follow-up protocol is unchanged by adjuvant radiotherapy, omitting the need for more intensive surveillance (every 3–6 months CT for 3 years, then every 6 months for 2 years) as specified in the reference; this is a moderate factual omission."
  },
  "309": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly prioritizing osimertinib over durvalumab for EGFR-mutant NSCLC post-chemoradiation and explaining the rationale. However, it references the ADAURA trial, which studied resected (surgical) patients, not unresectable stage III post-chemoradiation, introducing a minor inaccuracy in context."
  },
  "310": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the interaction of the lipid supplement with biological macromolecules (lipoproteins/chylomicrons) and its relevance to the patient's condition, with no inaccuracies or omissions."
  },
  "311": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies modulation of transcription factor activity as the primary mechanism, elaborates on zinc's role, and provides relevant supporting details. However, it introduces some ambiguity by discussing bismuth and does not state as concisely as the reference that modulation of transcription factor activity is the key mechanism, constituting a minor wording inaccuracy."
  },
  "312": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and relevant explanations about symptom relief and indications, and contains no inaccuracies or omissions."
  },
  "313": {
    "score": 5.0,
    "explanation": "5: Fully correct; all key facts from the reference are included, with additional relevant and accurate explanation about beta-blockers and their mechanism, without any inaccuracies or omissions."
  },
  "314": {
    "score": 2.0,
    "explanation": "2: The model answer provides several plausible mechanisms attributed to milk thistle, but the reference answer clearly states that the mechanism is unknown; thus, the model introduces moderate factual inaccuracies by presenting unproven mechanisms as established, despite a disclaimer about inconclusive evidence."
  },
  "315": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT and brain MRI are not indicated without suspicion of recurrence, and provides correct, relevant elaboration on surveillance protocols without any inaccuracies or omissions."
  },
  "316": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the supplement as chondroitin sulfate and accurately describes its effects on the extracellular matrix, covering the key concept of biological macromolecular activity; however, it does not explicitly use the term \"biological macromolecular activity,\" which is the precise answer required."
  },
  "317": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the enzyme inhibited, explains the mechanism, and relates it to NSAIDs and symptom relief, but does not specifically name COX-2 (Prostaglandin G/H Synthase 2) as the most directly relevant isoform, which is a minor omission."
  },
  "318": {
    "score": 3.0,
    "explanation": "3: The model answer recommends FDG-PET/CT as part of the initial evaluation for a new nodule, which is more aggressive than the reference answer, which reserves PET/CT and brain MRI for confirmed recurrence or strong suspicion of metastasis. While the explanation is reasonable and not unsafe, it does not fully align with the reference standard and overstates the role of PET/CT at this stage."
  },
  "319": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that switching to selpercatinib is appropriate and explains the rationale, but it omits that completing the current systemic therapy is also an acceptable option. It presents switching as the only or preferred approach, missing the individualized aspect and the acceptability of both strategies."
  },
  "320": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes dopamine reuptake inhibition as the primary mechanism, and provides additional correct and relevant details without any inaccuracies or omissions."
  },
  "321": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the drug class (alkylating agents), accurately describes their mechanism (DNA cross-linking and inhibition of replication), and relates this to the therapeutic effect in myelodysplastic syndrome, fully covering the key clinical facts in the reference answer."
  },
  "322": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism of action and the tetracycline class, but does not directly state \"protein synthesis inhibitors\" as required by the reference answer, missing the broader pharmacological class. It otherwise provides accurate and relevant clinical context."
  },
  "323": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies interferons/cytokines as the class, which is relevant, but does not mention \"biological response modifiers,\" the key term in the reference. It covers most key facts but omits the primary pharmacologic class as specified."
  },
  "324": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the IL-6 receptor as the molecular target, explains the clinical context, and provides accurate, relevant details without any omissions or inaccuracies."
  },
  "325": {
    "score": 2.0,
    "explanation": "2: The model answer does not mention \"Organic Anion Transporter 3\" and instead discusses dicarboxylate and ABC transporters, which are not the specific target referenced. While it provides some relevant background, it misses the key fact and introduces moderate inaccuracies regarding the exact transporter class."
  },
  "326": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts from the reference, clearly stating that adjuvant therapy consideration is based on additional high-risk features and not solely on stage IB and negative margins, with correct and relevant elaboration and no inaccuracies."
  },
  "327": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug and its main known actions, and acknowledges that the precise mechanism is incompletely understood, but provides more mechanistic detail than the reference, which simply states the mechanism is unknown; this is a minor wording inaccuracy but does not alter the clinical meaning."
  },
  "328": {
    "score": 4.0,
    "explanation": "4: The model answer covers the key fact that the precise mechanism is unknown, while also providing correct and relevant background on vitamin K's general role; there are no inaccuracies, but the extra mechanistic detail is not explicitly stated in the reference."
  },
  "329": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies inhibition of ergosterol synthesis and the importance of this pathway, but incorrectly names lanosterol 14-alpha-demethylase (target of azoles) instead of squalene epoxidase (target of allylamines), which is a moderate factual error."
  },
  "330": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies a constitutively active fusion tyrosine kinase and discusses imatinib's mechanism, but incorrectly names FIP1L1-PDGFRA instead of BCR-ABL as the primary target in this scenario, missing the key fact from the reference answer."
  },
  "331": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and explains the mechanism, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary isoform relevant to anti-inflammatory effects, missing a key detail from the reference answer."
  },
  "332": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for prioritizing chemotherapy in visceral crisis, and contains no inaccuracies or omissions."
  },
  "333": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly identifies demeclocycline as the relevant antibiotic, and explains its effect on ADH responsiveness via inhibition of protein synthesis, though it could more directly state \"protein synthesis inhibitors\" as the drug class. Minor omission of explicitly naming \"protein synthesis inhibitors\" as the class prevents a perfect score."
  },
  "334": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing systemic therapy due to active disease progression, and adds relevant considerations about patient assessment and multidisciplinary input without introducing inaccuracies or irrelevant content."
  },
  "335": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies selective glucocorticoid receptor modulators, accurately describes their mechanism, and addresses their clinical advantages, fully covering all key facts in the reference answer with relevant, correct elaboration."
  },
  "336": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the erythropoietin receptor activation, and provides additional correct and relevant mechanistic detail without any inaccuracies or omissions."
  },
  "337": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant and accurate details about specific endocrine therapy options, and contains no inaccuracies or omissions."
  },
  "338": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the general target as G protein-coupled receptors and provides accurate, relevant detail about adenosine and its mechanism, but omits the broader term \"structural macromolecules\" and the specific reference to \"purinergic receptors,\" which are both present in the reference answer."
  },
  "339": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug and its mechanism but gives \"antimetabolite\" and \"antineoplastic agent\" as the pharmacological class, rather than the more precise \"nucleic acid synthesis inhibitors\" as in the reference; this is a minor but relevant omission, covering about 70-89% of key facts."
  },
  "340": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies nitazoxanide and its mechanism but does not mention \"uncouplers,\" missing the key fact required by the question; it also inaccurately describes the molecular action as quinolones, which is incorrect in this context."
  },
  "341": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly stating that non-contrast CT is appropriate and effective for surveillance in this scenario, and explains the rationale. The suggestion to consider MRI or PET is extra but relevant; however, the statement that contrast CT \"can provide more detailed images\" is a minor wording inaccuracy, as contrast is not generally required for lung parenchymal assessment, warranting a slight deduction."
  },
  "342": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies phospholipase A2 instead of lipoxygenase as the principal enzyme, which is a moderate factual error, though the explanation of corticosteroid mechanism is otherwise accurate."
  },
  "343": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, accurately explains the rationale for adjuvant chemoradiation, and correctly states that management would change if distant metastases were present; all additional content is relevant and correct."
  },
  "344": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the necessity of pathologic confirmation, and provides relevant, correct additional detail about staging methods and rationale, with no inaccuracies or omissions."
  },
  "345": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed, accurate description of the proposed mechanism of metronidazole but omits the key fact from the reference that the precise molecular mechanism in bacterial vaginosis remains unclear; thus, it overstates certainty and misses a critical nuance."
  },
  "346": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant, correct details about symptom management and the role of chemoradiation, with no inaccuracies or omissions."
  },
  "347": {
    "score": 4.0,
    "explanation": "4: The model answer accurately describes the agent's role as a substrate/cofactor in mitochondrial energy metabolism and its effect on cellular processes, but it does not explicitly use the term \"biological macromolecular activity\" as in the reference, representing a minor omission in terminology."
  },
  "348": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies polyenes (e.g., amphotericin B) as the drug class and accurately describes their mechanism, but it does not explicitly state that the mechanism is most closely related to ergosterol synthesis inhibitors, as required by the question; this is a minor omission."
  },
  "349": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies lipoxygenases as the enzyme class, explains their role in leukotriene synthesis, and accurately describes the mechanism, with no omissions or inaccuracies."
  },
  "350": {
    "score": 3.0,
    "explanation": "3: The model answer covers the importance of systemic therapy and the potential role of local therapy for oligometastatic disease, but it omits the key recommendation to combine local therapy for the metastasis with concurrent chemoradiation for the primary site upfront, as stated in the reference. It also incorrectly suggests deprioritizing concurrent chemoradiation, which is a moderate omission."
  },
  "351": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP2C8 as the inhibited enzyme instead of CYP2C19, which is the key fact in the reference answer; while the explanation of clinical significance is generally correct, this moderate factual error lowers the score."
  },
  "352": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly stating that severely reduced pulmonary function makes surgery high risk and suggesting radiotherapy as an alternative, but it is less direct than the reference in contraindicating surgery and could be clearer that surgery is generally not appropriate in this context."
  },
  "353": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the importance of brain MRI and PFTs, but incorrectly suggests that PFTs are not a strict prerequisite and that systemic therapy may sometimes be started before these assessments, which omits the reference answer's clear requirement for both tests prior to therapy."
  },
  "354": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly prioritizes further endocrine therapy despite clear evidence of endocrine resistance, directly contradicting the reference answer and current guidelines; this is a major inaccuracy that could lead to suboptimal care."
  },
  "355": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the anaplerotic action and explains the metabolic effects, but it does not explicitly state the general pharmacological action as \"biological macromolecular activity,\" missing the key classification required by the question."
  },
  "356": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, emphasizing the need to distinguish between metastatic disease and separate primaries, and notes that curative resection may be appropriate if they are separate primaries. It adds relevant detail about multidisciplinary evaluation and histology, but is slightly less direct than the reference in stating that, if both are potentially curable and the patient is operable, they should be treated as separate primaries."
  },
  "357": {
    "score": 3.0,
    "explanation": "3: The model answer discusses relevant aspects of Ménière's disease and mentions modulation of ion channels, including calcium and potassium channels, but does not specifically and directly identify \"calcium channel interactions\" as the primary class, and instead gives a less precise answer (\"vestibular system ion channels\"), missing the key fact required."
  },
  "358": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need for both lesions to be individually resectable and potentially curable, but introduces ambiguity by suggesting surgical management does not implicitly require treating them as two primaries, which contradicts the reference. It also adds correct but somewhat tangential detail about evaluation, but overall lacks clarity on the implicit requirement stated in the reference."
  },
  "359": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing that immunotherapy monotherapy is not appropriate and that platinum-based chemotherapy is standard; it also accurately discusses combination chemoimmunotherapy as a possible option, which is clinically relevant. There is a minor omission in not explicitly stating that immunotherapy is generally reserved for higher PD-L1 or post-chemotherapy, but overall, the answer is thorough and accurate."
  },
  "360": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed, accurate description of nintedanib’s known pharmacologic targets and antifibrotic effects, but does not emphasize that the precise molecular mechanism in IPF remains unknown, as required by the reference answer."
  },
  "361": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately describes both heme detoxification interference and inhibition of nucleic acid synthesis, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "362": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the drug as apremilast (a PDE4 inhibitor) rather than modified cyclosporine, which is the agent described in the reference; this is a moderate factual error, though it does mention the mechanism is incompletely defined."
  },
  "363": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine PET/CT or brain MRI is not indicated, and appropriately describes standard surveillance; all additional explanations are correct and clinically relevant."
  },
  "364": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rarity of actionable mutations in squamous cell carcinoma, and correctly states that molecular testing is not essential before perioperative therapy, with no inaccuracies or omissions."
  },
  "365": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that 3–6 month CT surveillance is appropriate, missing the key guideline that 6-month intervals are recommended for stage II post-surgical patients without radiotherapy; this is a major factual error."
  },
  "366": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that adjuvant radiotherapy is generally recommended but acknowledges individualized decision-making and multidisciplinary discussion. However, it underemphasizes that surveillance without immediate radiotherapy is acceptable within standard management if re-resection or systemic therapy is pursued, and overstates that surveillance is not generally within guidelines, missing the nuance in the reference."
  },
  "367": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains cilostazol’s mechanism and the role of cAMP in vasodilation, but it incorrectly identifies adenosine A2 receptors as the primary GPCR target, rather than beta-adrenergic receptors as specified in the reference; this is a moderate factual error, though the explanation is otherwise relevant and not unsafe."
  },
  "368": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the antioxidant (free radical scavenging) mechanism and its effect on the ocular surface, with additional correct and relevant explanation."
  },
  "369": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly prioritizing local intervention for isolated, asymptomatic endobronchial obstruction and reserving systemic therapy for disseminated disease. There is a minor omission in not explicitly stating that local intervention is preferred as initial management, but this is implied; all extra content is relevant and accurate."
  },
  "370": {
    "score": 5.0,
    "explanation": "5: Accurately identifies cyclooxygenase (COX) as the molecular target, specifies COX-2, and correctly explains its role in converting arachidonic acid to pro-inflammatory mediators; all content is clinically relevant and correct."
  },
  "371": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies rifampicin as an RNA synthesis inhibitor and accurately describes its mechanism, but it does not use the broader class term \"nucleic acid synthesis inhibitors\" as in the reference, representing a minor omission in scope."
  },
  "372": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need for careful assessment and alternative strategies, but overstates the feasibility of concurrent chemoradiation as a standard option in patients with poor pulmonary function, which the reference suggests may contraindicate its use; this represents a minor inaccuracy and a slight overemphasis on feasibility."
  },
  "373": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that systemic adjuvant therapy is not routinely indicated and explains the rationale, but it introduces possible adjuvant endocrine therapy for hormone receptor-positive DCIS, which, while factually correct, is not specifically addressed in the reference and could be seen as a minor irrelevant addition. Otherwise, it covers all key facts without inaccuracies."
  },
  "374": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly noting that COPD does not alter the standard follow-up interval, and provides relevant, accurate context without any inaccuracies or omissions."
  },
  "375": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the mechanism as immune modulation/biological response modification, and provides relevant, correct additional detail without inaccuracies or omissions."
  },
  "376": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cytochrome P450 (specifically CYP1A2) as the relevant enzyme class, explains the induction mechanism, and accurately describes the clinical implications, fully covering all key facts from the reference answer without inaccuracies or omissions."
  },
  "377": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly asserts that adjuvant therapy is indicated regardless of mediastinal nodal assessment, missing the key fact that accurate nodal staging is essential for adjuvant therapy decisions; this is a moderate factual omission that affects clinical management."
  },
  "378": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting increased risks and the need for individualized decision-making, but it overstates the appropriateness of repeat radiotherapy and does not clearly state that prior RT is generally a contraindication, which is a key point in the reference answer."
  },
  "379": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that re-resection is preferred and radiotherapy is a secondary option if re-resection is not feasible, with no inaccuracies or omissions."
  },
  "380": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies Giardia and metronidazole, and accurately describes the general mechanism of DNA damage, but it incorrectly asserts that DNA is the most accurate molecular target, whereas the reference emphasizes that the precise cellular or molecular interaction is unknown—a key fact omitted."
  },
  "381": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the glycopeptide class and explains the mechanism of action, but it does not explicitly state \"enzyme inhibitor\" as the pharmacological class, which is the key fact in the reference answer. Otherwise, the explanation is accurate and relevant."
  },
  "382": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the risks of surgery in severe pulmonary impairment, and appropriately recommends non-surgical options like SBRT; additional content is accurate and clinically relevant."
  },
  "383": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 as the primary enzyme induced, rather than CYP2C19, which is specifically referenced in the question; while it correctly discusses carbamazepine and enzyme induction, this represents a moderate factual error."
  },
  "384": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need to consider thromboembolic risk and the differential use of tamoxifen and aromatase inhibitors, but incorrectly states that the recommendation \"typically assumes\" absence of risk, which is inaccurate. It also adds some relevant detail but lacks clarity that the recommendation does not universally assume absence of risk, as in the reference."
  },
  "385": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies immunomodulation as the mechanism and explains the role of recombinant cytokines in altering immune responses, closely matching the reference. It adds relevant context about disease pathology, but does not explicitly use the term \"biological response modifier,\" which is a minor omission."
  },
  "386": {
    "score": 2.0,
    "explanation": "2: The model answer identifies phospholipids and membrane lipids as targets but omits the specific engagement of lysophospholipid receptors, which is the key fact. It provides some relevant context but misses the precise molecular target class."
  },
  "387": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "388": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that the mechanism is not well-defined and describes the action as \"non-specific,\" but it does not explicitly use the term \"unknown cellular or molecular interaction\" and adds extra explanation that, while mostly correct, is not directly relevant to the precise term asked for."
  },
  "389": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts from the reference, correctly stating that surgery remains an option and systemic therapy is not automatically required. It adds accurate, relevant context about staging and multidisciplinary evaluation, but slightly overemphasizes the routine use of neoadjuvant therapy, which is not mandated in all such cases—this constitutes a minor inaccuracy in emphasis."
  },
  "390": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the therapy as eculizumab and its mechanism (C5 inhibition), but it fails to name C3, the specific complement protein asked for in the question, which is a moderate factual omission."
  },
  "391": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the presumed mechanism of exogenous lactase action but does not acknowledge that the precise cellular or molecular mechanism is unknown, as emphasized in the reference; it covers most key facts but omits the central uncertainty."
  },
  "392": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key point that the mechanism is unclear in hepatic trematode infections and provides accurate, relevant background on metronidazole's known mechanism in other organisms. However, it incorrectly identifies the drug as metronidazole rather than emetine hydrochloride, which is a moderate factual error, and thus misses the specific reference answer's focus."
  },
  "393": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism of action and identifies the drug class as beta-lactam antibiotics, but it does not directly state \"enzyme inhibitors\" as required by the reference answer, missing the key fact that the mechanism is best described as enzyme inhibition."
  },
  "394": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies dantrolene, its mechanism, and its pharmacological class, with no inaccuracies or omissions."
  },
  "395": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing that adjuvant radiation is generally recommended but surveillance may be considered in select cases, and highlights the need for individualized, multidisciplinary decision-making. There is a minor wording inaccuracy in suggesting PORT is \"generally indicated\" rather than explicitly stating it is not always mandatory, but this does not alter the clinical meaning."
  },
  "396": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies zinc and its antiviral effects but omits the key reference mechanism of acid-base activity (altering local pH), instead focusing on viral attachment and replication inhibition, which is less directly relevant to the question's emphasis."
  },
  "397": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the clinical context and discusses relevant receptor mechanisms (D2, H1, muscarinic), but it omits the key fact from the reference answer—adrenergic alpha-antagonism—as the most relevant mechanism in this context, constituting a moderate omission."
  },
  "398": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the sequence of chemoradiation does not affect surveillance frequency and describes the standard CT surveillance intervals, but it introduces minor wording differences (e.g., specifying \"first two years\" instead of \"first three years\") and adds less relevant points about institutional guidelines and clinical judgment, which slightly detract from precision."
  },
  "399": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the disease and mechanism but does not use the specific pharmacologic class \"enzyme activators\" as in the reference; instead, it uses broader terms like \"hemostatic agent,\" which is less precise."
  },
  "400": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that routine PET/CT and brain MRI are not recommended and that surveillance should focus on scheduled chest CT scans, with additional imaging reserved for clinical suspicion; all extra content is correct and clinically relevant."
  },
  "401": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of key facts, accurately describing the proposed anti-inflammatory mechanisms of omega-3s and noting that the exact pathways in Sjögren's are not fully delineated; however, it could more clearly emphasize that the precise mechanism remains unclear, as in the reference."
  },
  "402": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but understates the recommended frequency (every 6 months instead of every 3–6 months), omits mention of history & physical examination, and does not note that this schedule is more frequent than for stage I–II post-surgical cases."
  },
  "403": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that local palliative interventions remain possible after chemotherapy, and adds relevant, correct context about clinical decision-making without any inaccuracies or omissions."
  },
  "404": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly stating that dabrafenib plus trametinib is generally started after completion or interruption of current therapy, but introduces a minor inaccuracy by suggesting it can be used as first-line and that immediate switch may be considered, which is not standard; however, it does not provide unsafe advice."
  },
  "405": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, correctly identifies rifamycins as the drug class, accurately describes their mechanism, and provides a relevant example without any inaccuracies or omissions."
  },
  "406": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly stating that both lesions must be potentially curable to be treated as separate primaries, and provides relevant additional context. There is a minor wording inaccuracy regarding the typical interpretation of M1a, but this does not alter the core meaning."
  },
  "407": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies that iron supplementation enhances hemoglobin synthesis and addresses iron deficiency anemia, covering most key facts, but does not explicitly mention iron transport/utilization or the role of electrolyte activity as in the reference answer."
  },
  "408": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the likely drug (albendazole) and its mechanism, but gives the pharmacological class as \"benzimidazoles\" rather than the broader \"enzyme inhibitors\" as required by the reference; about 70-89% of key facts are covered, but the specific class asked for is not directly stated."
  },
  "409": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for both biopsies, and provides clinically relevant additional detail without any inaccuracies or omissions."
  },
  "410": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing immediate SVC stenting for symptom relief before chemoradiation, and provides accurate, relevant explanations without any inaccuracies or omissions."
  },
  "411": {
    "score": 4.0,
    "explanation": "4: The answer correctly identifies cyclooxygenase (COX) as the target and explains the mechanism, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary isoform relevant to the therapeutic effect, which is a minor omission."
  },
  "412": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that fam-trastuzumab deruxtecan-nxki can be justified in squamous cell carcinoma with ERBB2 mutation and that targeted therapy is not limited to adenocarcinoma; additional content is accurate and clinically relevant."
  },
  "413": {
    "score": 1.0,
    "explanation": "1: The model answer omits the key fact that brain MRI is routinely indicated for initial staging in stage II NSCLC and incorrectly states it is not necessary unless symptomatic, which is a major inaccuracy that could lead to under-staging and inappropriate management."
  },
  "414": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant facts but omits the key point that confirmation of non-squamous histology is standard before initiating ROS1-targeted therapy, and incorrectly suggests that histology is irrelevant if a ROS1 rearrangement is found, which is not consistent with guidelines."
  },
  "415": {
    "score": 4.0,
    "explanation": "4: The answer correctly identifies opioids as the pharmacologic class, explains mu-opioid receptor action in the medullary cough center, and provides relevant detail. However, mentioning dextromethorphan as acting on \"similar pathways\" is a minor inaccuracy, as it is not a mu-opioid agonist, slightly detracting from precision."
  },
  "416": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the clinical scenario, the role of fibrinogen, and the mechanism of replacement therapy, but it does not identify \"enzyme activators\" as the pharmacological class, instead using broader terms like \"hemostatic agent\" or \"hemoconcentrate,\" which misses the key fact required by the reference answer."
  },
  "417": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies muscarinic acetylcholine receptors as the molecular target, provides accurate and clinically relevant additional detail about the M3 subtype and mechanism, and contains no inaccuracies or omissions."
  },
  "418": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine brain MRI is not indicated, and provides additional relevant explanation without inaccuracies or omissions."
  },
  "419": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies RNA polymerase inhibitors as the drug class, specifies fidaxomicin, accurately describes its mechanism, and relates it to C. difficile treatment, covering all key clinical facts without errors or omissions."
  },
  "420": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the therapy as a procoagulant and explains its mechanism, but it omits the more specific and required term \"enzyme activators\" from the reference answer, which is a key fact."
  },
  "421": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD19 as the target, accurately describes its expression pattern, and provides clinically relevant context about its role in NMOSD without any inaccuracies or omissions."
  },
  "422": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that routine FDG-PET/CT is not recommended, describing standard surveillance, and noting PET/CT is reserved for suspected recurrence; additional details are accurate and clinically relevant."
  },
  "423": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, emphasizing the importance of confirming receptor status at recurrence, but introduces the caveat of relying on primary tumor status if biopsy is not feasible, which is a minor omission compared to the reference's stronger recommendation for biopsy confirmation. No clinically unsafe advice is given."
  },
  "424": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies antihistamines as the class with a similar mechanism, omitting serotonin antagonists, which are the correct answer; it covers some relevant pharmacology but misses the key fact and contains a moderate factual error."
  },
  "425": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferons and provides accurate mechanistic details, but it does not use the broader pharmacological class \"Biological Response Modifiers\" as required by the reference, thus missing a key fact."
  },
  "426": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism of action of dupilumab (IL-4Rα blockade affecting both IL-4 and IL-13 signaling), but does not directly name IL-13 as the molecular target as required by the reference answer, resulting in a moderate omission."
  },
  "427": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the drug and its immunomodulatory effects but does not explicitly state the pharmacologic class as \"immunologic adjuvant,\" which is the key fact required; otherwise, the mechanistic explanation is accurate and relevant."
  },
  "428": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, acknowledging the benefit of pre-treatment axillary biopsy and marker placement, but incorrectly suggests that proceeding without biopsy is generally appropriate, which contradicts guideline-based recommendations and omits the importance of accurate pre-treatment staging."
  },
  "429": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies C5 inhibition, explains the mechanism, and provides relevant, accurate elaboration without any inaccuracies or omissions."
  },
  "430": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately noting that moderate renal insufficiency does not preclude preoperative systemic therapy but may require regimen adjustment and monitoring; additional details about specific agents and multidisciplinary management are correct and clinically relevant."
  },
  "431": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly noting that surgery is standard if tolerated but that SBRT is preferred for high-risk patients with impaired PFTs; it adds relevant detail about SBRT and multidisciplinary evaluation, but the initial emphasis on surgery as standard could be clearer that significant PFT impairment usually shifts first-line preference to SBRT."
  },
  "432": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that routine brain MRI is not indicated in asymptomatic, resected Stage IIB NSCLC, and provides relevant, accurate context without any inaccuracies or omissions."
  },
  "433": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes bismuth’s cytoprotective action and barrier formation, but it omits the key reference point of acid-base activity and modulation of gastric pH, which is central to the reference answer."
  },
  "434": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing immediate local management in cases of imminent fracture risk, and appropriately discusses subsequent initiation of systemic therapy. Additional content is accurate, relevant, and does not detract from the core message."
  },
  "435": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key facts from the reference (binding to bone, inhibiting osteoclast-mediated resorption) and adds accurate, clinically relevant molecular detail about the mevalonate pathway and osteoclast apoptosis, with no inaccuracies or omissions."
  },
  "436": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine brain MRI is not recommended, and appropriately describes standard follow-up and indications for brain MRI, with no inaccuracies or omissions."
  },
  "437": {
    "score": 2.0,
    "explanation": "2: The model answer provides a specific mechanism of action (inhibition of isoleucyl-tRNA synthetase by mupirocin), which contradicts the reference answer stating the mechanism is unknown; this is a moderate factual error and does not align with the key fact required."
  },
  "438": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the role of amivantamab and mobocertinib for EGFR exon 20 insertions but incorrectly states that platinum-based chemotherapy remains first-line, relegating targeted therapy to subsequent lines, which omits the key fact that targeted agents are now recommended as first-line if available; otherwise, the content is accurate and relevant."
  },
  "439": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that observation is not appropriate, directly contradicting the reference answer, which allows for observation in select cases. While the model provides relevant discussion of alternative treatments, this moderate factual error regarding the appropriateness of observation warrants a score of 2."
  },
  "440": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on mast cell stabilization and inhibition of calcium influx, which is accurate for mast cell stabilizers but does not address the reference answer's key fact—direct histamine H1 receptor antagonism. This represents a moderate omission of the primary molecular target described in the reference."
  },
  "441": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switch to osimertinib, omitting the key fact that current therapy should be completed first, and thus provides potentially confusing and inappropriate clinical advice."
  },
  "442": {
    "score": 2.0,
    "explanation": "2: The answer incorrectly identifies the drug class as β1-adrenergic agonists instead of dopamine agonists, which is a moderate factual error, though the mechanism is otherwise described accurately. About half of the key facts are covered, but the main pharmacological class is wrong."
  },
  "443": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism of glucocorticoids (phospholipase A2 inhibition) but does not directly identify lipoxygenase inhibitors as the answer, missing the key fact required by the question and reference. It covers most relevant physiology but lacks the specific enzyme class asked."
  },
  "444": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing re-resection over radiation and appropriately noting radiation as an alternative if re-resection is not feasible, with all additional content being accurate and clinically relevant."
  },
  "445": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the Fc receptor blockade mechanism, which is a key immunological effect of IVIG in autoimmune hemolytic anemia, but it does not mention neutralization of pathogenic autoantibodies (the reference answer's focus). It also includes some correct but less central mechanisms, covering about 70-89% of key facts."
  },
  "446": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending continued HER2-targeted therapy when it is no longer indicated, which is a major clinical inaccuracy and could lead to inappropriate treatment."
  },
  "447": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the drug as pregabalin instead of gabapentin enacarbil and provides a specific mechanism of action, whereas the reference emphasizes that the precise mechanism is unknown; this constitutes a moderate factual error and covers less than 70% of key facts."
  },
  "448": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, with additional correct and clinically relevant explanation of the mechanism; no inaccuracies or omissions."
  },
  "449": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies concurrent chemoradiation as the preferred initial treatment, and provides relevant, accurate rationale without any omissions or inaccuracies."
  },
  "450": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies competitive inhibition as the mechanism and accurately explains how the drug competes with PABA at the enzyme's active site, but it omits explicitly naming \"PABA inhibitors\" as the class, which is a minor omission."
  },
  "451": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that broad molecular profiling is still recommended regardless of squamous histology and instead suggests limiting testing, which is a moderate factual error. It also fails to mention other actionable mutations (e.g., BRAF, MET) and does not align with current guidelines for advanced disease."
  },
  "452": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies dantrolene and its mechanism but names \"ryanodine receptor antagonists\" rather than \"calcium channel antagonists\" as the pharmacological class, missing the key fact required by the reference."
  },
  "453": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the prostaglandin FP receptor as the most directly responsible, missing the key fact that the question describes a sympathetic GPCR (beta2-adrenergic receptor); while the explanation about prostaglandins is factually correct, it is not relevant to the specific mechanism described, constituting a moderate factual error."
  },
  "454": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the importance of pathologic confirmation and the standard of care, but introduces the possibility of proceeding without biopsy in select cases, which is not supported by the reference and could lead to inappropriate management; this constitutes a moderate omission."
  },
  "455": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies corticosteroids and their inhibition of phospholipase A2, which is upstream of leukotriene synthesis, but does not directly answer the question regarding lipoxygenase inhibitors as the enzyme class that directly inhibits leukotriene synthesis; thus, it covers most but not all key facts."
  },
  "456": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies phosphodiesterase 5 (PDE5) as the enzyme responsible for cGMP degradation, matching the reference answer's key fact; wording is accurate and clinically relevant."
  },
  "457": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies microtubules as the structure disrupted and explicitly states that the agent binds tubulin, matching the reference answer. All key facts are covered with relevant, accurate elaboration."
  },
  "458": {
    "score": 2.0,
    "explanation": "2: The model answer correctly describes the mechanism of urea and its effects but fails to provide the key term \"physiochemical activity\" as required, instead using \"keratolytic and humectant,\" which is less precise for the mechanistic class asked."
  },
  "459": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the pharmacologic class as GnRH antagonists and accurately explains the mechanism by which suppression of LH/FSH and subsequent estrogen reduction alleviates endometriosis symptoms, with all key clinical facts covered and no inaccuracies."
  },
  "460": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and explains the mechanism, but incorrectly emphasizes COX-2 as the primary target, whereas the reference specifies COX-1; this represents a minor but clinically relevant inaccuracy."
  },
  "461": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies inhibition of HMG-CoA reductase and provides additional, accurate, and clinically relevant explanation of downstream effects (LDL receptor upregulation and increased LDL clearance), with no inaccuracies or omissions."
  },
  "462": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies degradation of TTR mRNA via RNA interference and explains the mechanism, but it inaccurately states that the therapy \"disrupts the process of translation\" rather than mRNA stability; this is a minor wording inaccuracy that does not alter the essential meaning."
  },
  "463": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating re-resection as preferred and radiotherapy as appropriate when surgery is not feasible due to comorbidities or anatomical limitations. Additional points about patient preference and multidisciplinary discussion are relevant and accurate."
  },
  "464": {
    "score": 2.0,
    "explanation": "2: The model answer does not identify the key property—antioxidant/free radical scavenging activity—and instead incorrectly focuses on disruption of amyloid precursor folding, which is not the mechanism of the described medication. It covers some relevant background but omits the main clinical fact."
  },
  "465": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies miltefosine and its general mechanism but incorrectly specifies the PI3K-Akt pathway rather than lysophospholipid receptor interactions, which is the primary molecular target per the reference; this constitutes a moderate factual error."
  },
  "466": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains the mechanism, but does not specifically name COX-2 (prostaglandin G/H synthase 2) as the most directly relevant isoform for the anti-inflammatory effect, representing a minor omission."
  },
  "467": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism of action and class (β-lactam antibiotics) but does not explicitly state \"enzyme inhibitors\" as required by the reference answer, missing the key pharmacological classification."
  },
  "468": {
    "score": 3.0,
    "explanation": "3: Identifies cytochrome P450 enzymes and specifically CYP3A4 as responsible for increased clearance, but omits the key fact that CYP1A inducers are most relevant per the reference answer; otherwise, the explanation is accurate and relevant."
  },
  "469": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting the appropriateness of switching to crizotinib and the relevance of ALK rearrangements, but omits that either completing current therapy or switching are both acceptable options based on clinical judgment; it also overstates the need to interrupt therapy, missing the nuance of individualized decision-making."
  },
  "470": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies that the mechanism is not fully understood and provides accurate, relevant details about cyclobenzaprine’s central action, but it slightly overstates the specificity of its mechanism (e.g., noradrenergic pathways, brainstem inhibition), which is not definitively established, representing a minor inaccuracy."
  },
  "471": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that intensive surveillance is appropriate for all resected stage III patients, not distinguishing the specific recommendation for those who received radiotherapy; this is a moderate factual inaccuracy, though the rest of the content is relevant and not unsafe."
  },
  "472": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug as Rifampin and its mechanism as RNA polymerase inhibition, but does not explicitly use the broader class term \"Nucleic Acid Synthesis Inhibitors\" as in the reference; otherwise, all key facts are present."
  },
  "473": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly emphasizing adjuvant radiotherapy as standard after R1 resection and the need for individualized decision-making, but it incorrectly suggests that surveillance alone may be reasonable in selected patients, which is not supported by guidelines and omits re-resection as the preferred option."
  },
  "474": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 as the key pathway instead of CYP1A, which is specifically referenced in the standard answer; while it provides relevant background and discusses drug interactions, this represents a moderate factual error regarding the specific enzyme involved."
  },
  "475": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes systemic therapy over repeat radiotherapy due to toxicity risks, and adds relevant, accurate details about treatment individualization and multidisciplinary input without any inaccuracies or omissions."
  },
  "476": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends FDG-PET/CT as the next step for an asymptomatic radiographic abnormality in routine surveillance, which is not standard per guidelines; it also omits that both PET/CT and brain MRI are reserved for suspected recurrence, not routine follow-up, thus missing key clinical facts."
  },
  "477": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant details about surgical options and rationale, and contains no inaccuracies or omissions."
  },
  "478": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies serotonin reuptake inhibition as the mechanism, provides accurate additional context about SSRIs/SNRIs, and explains the clinical relevance without any inaccuracies or omissions."
  },
  "479": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the mechanism as inhibition of enzymes involved in cell wall synthesis and accurately names beta-lactam antibiotics, which are enzyme inhibitors; however, it does not explicitly use the general term \"enzyme inhibitors\" as in the reference, representing a minor wording inaccuracy."
  },
  "480": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes a major mechanism of IVIG (Fc receptor blockade), but omits the principal mechanism referenced (neutralization of pathogenic autoantibodies). It covers most key facts but misses the most direct mechanism, resulting in a moderate omission."
  },
  "481": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the need for caution or avoidance of ceritinib in hepatic impairment and the recommendation to consider alternative ALK inhibitors like alectinib; all additional content is accurate and clinically relevant."
  },
  "482": {
    "score": 1.0,
    "explanation": "1: The model answer does not identify asparagine as the direct target, instead focusing on cholesterol and methionine, which are incorrect in this context; it misses the key clinical fact and provides mostly irrelevant reasoning."
  },
  "483": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GABA_B receptor as the primary target, accurately explains the clinical context, and provides relevant, factually correct additional information without any inaccuracies or omissions."
  },
  "484": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the pharmacologic class and mechanism, and provides additional accurate, clinically relevant detail without inaccuracies or omissions."
  },
  "485": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends annual imaging instead of the guideline-supported every six months, omitting a key fact and providing a moderate factual error regarding surveillance frequency."
  },
  "486": {
    "score": 2.0,
    "explanation": "2: The model answer correctly describes the mechanism of PDE3 inhibitors, which are indeed used for intermittent claudication, but it does not identify the reference class (beta-agonists) and thus misses the key fact about the specific receptor type and class asked in the question."
  },
  "487": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism of action and identifies the class as \"antifibrinolytic agents,\" which is accurate but less specific than \"plasmin inhibitors\"; otherwise, all key facts are covered with no clinically relevant errors."
  },
  "488": {
    "score": 3.0,
    "explanation": "3: The answer correctly explains corticosteroids' inhibition of phospholipase A2 and its effect on leukotriene synthesis, but it fails to directly identify \"lipoxygenase enzymes\" as the class most directly inhibited in the context of the question, and contains some ambiguity regarding the directness of inhibition, missing the key fact required by the reference."
  },
  "489": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that chemoradiation is indicated for R1 resection regardless of prior adjuvant chemotherapy, and provides additional relevant clinical context without inaccuracies or omissions."
  },
  "490": {
    "score": 4.0,
    "explanation": "4: Covers all key facts except for a minor omission—the recommended surveillance interval can be every 3–6 months, but the model answer only specifies every 6 months; otherwise, the modality and rationale are correct and clinically relevant."
  },
  "491": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes standard surveillance, and correctly states that advanced imaging is reserved for suspicion of recurrence; no inaccuracies or omissions are present."
  },
  "492": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the need for absence of distant metastases confirmed by FDG-PET/CT and brain MRI before recommending surgery, with no inaccuracies or omissions."
  },
  "493": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the importance of distinguishing between primary tumors and metastases, and the implications for management. However, it introduces ambiguity by emphasizing histological and molecular differences as the main determinant, rather than clearly stating that, per staging conventions, these lesions should be managed as synchronous primaries in the absence of nodal or distant disease. This represents a minor omission and a slight inaccuracy in clinical emphasis."
  },
  "494": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies carbohydrates (specifically glycogen) as the replenished macromolecule and accurately describes glucose utilization and symptom correction; however, it slightly overemphasizes ATP production rather than focusing solely on glycogen as the structural macromolecule, representing a minor wording inaccuracy."
  },
  "495": {
    "score": 3.0,
    "explanation": "3: The model answer covers the antimicrobial effects and the creation of a mildly acidic environment, but it emphasizes antimicrobial action rather than the primary acid-base activity mechanism specified in the reference. There is a minor misalignment in focus, but most key facts are present and there are no unsafe statements."
  },
  "496": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical syndrome, the vitamin involved, and its biochemical role, but it does not explicitly state the general pharmacological class as \"enzyme activators\" as in the reference answer, instead focusing on \"vitamin supplement and coenzyme precursor,\" which is less precise for the question asked."
  },
  "497": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes downstream signaling (ISGF3) but omits the essential role of the interferon alpha receptor complex as the primary mediator, which is the focus of the question; it covers much of the relevant pathway but misses the key fact required."
  },
  "498": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies nucleotide/nucleoside analogs as the pharmacological class and accurately describes their mechanism, but it omits the broader class term \"enzyme inhibitors\" used in the reference answer; this is a minor omission as nucleotide/nucleoside analogs act as enzyme inhibitors."
  },
  "499": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and explains the mechanism, but incorrectly specifies COX-2 as the primary target, whereas the reference answer is COX-1; this is a moderate factual inaccuracy but not clinically dangerous."
  },
  "500": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need for CNS assessment and the impact of CNS status on ALK inhibitor selection, but it inaccurately suggests that crizotinib can be initiated without CNS imaging, which contradicts the reference's emphasis on establishing CNS status prior to therapy decision."
  },
  "501": {
    "score": 2.0,
    "explanation": "2: The model answer describes several effects of hyperbaric oxygen therapy but does not mention the primary molecular mechanism of free radical scavenging activity; instead, it focuses on oxygen delivery, inhibition of bacterial growth, and wound healing, which are secondary effects, resulting in a moderate omission."
  },
  "502": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizes the importance of broad molecular profiling in squamous NSCLC with a KRAS G12C mutation, and provides relevant, correct additional context without any inaccuracies or omissions."
  },
  "503": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts standard clinical practice by recommending immediate initiation of ROS1-targeted therapy rather than completing the current regimen, which is a major inaccuracy and could lead to inappropriate management."
  },
  "504": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CCR4 instead of CXCR4 as the molecular target, which is a moderate factual error, though the rest of the explanation is relevant and not unsafe."
  },
  "505": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that palliative chemotherapy can be considered for both symptomatic and asymptomatic patients, and adds relevant, accurate context without any inaccuracies or omissions."
  },
  "506": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the medication as a somatostatin analog and explains its mechanism, but incorrectly states SSTR2 as the primary target instead of SSTR5, which is the key fact in the reference answer."
  },
  "507": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies aminoglycosides and accurately describes their mechanism, but it does not use the broader class \"protein synthesis inhibitors\" as required by the question, omitting the key fact from the reference answer."
  },
  "508": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the need for pathological confirmation of N3 disease and pulmonary function testing before initiating systemic therapy, and provides additional relevant and accurate detail without any inaccuracies or omissions."
  },
  "509": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as tetracyclines and accurately describes their mechanism, but it does not explicitly state the broader class \"protein synthesis inhibitors\" as required by the question; otherwise, all key facts are present and relevant."
  },
  "510": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PPAR activation as the mechanism, omitting the key fact that the drug is a thyroid hormone receptor agonist; while the explanation is relevant to nuclear receptors and liver disease, the main mechanism is moderately misidentified."
  },
  "511": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the acidification and ammonia trapping mechanism but omits the key fact that the primary pharmacologic property is the medication's osmotic activity, as specified in the reference answer."
  },
  "512": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing PD-1/PD-L1 inhibitor monotherapy and providing a relevant example without inaccuracies or omissions."
  },
  "513": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the mechanism (enzyme inhibition of carbonic anhydrase) and its relevance to acid-base regulation, but it does not use the reference's broader mechanistic category (\"biological macromolecular activity\"), which is required by the question."
  },
  "514": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the adjunct drug as artesunate rather than pentoxifylline and provides an inaccurate mechanism related to artesunate, not the adjunct in question. While some discussion of microcirculation and inflammation is present, the key fact—that the mechanism in cerebral malaria is unknown—is omitted."
  },
  "515": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies dihydrofolate reductase inhibitors as the drug class, which is a specific subset of folic acid metabolism inhibitors, and provides relevant clinical context. However, it does not explicitly state the broader class \"folic acid metabolism inhibitors\" as in the reference, representing a minor omission in scope."
  },
  "516": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly distinguishing between synchronous primaries and intrapulmonary metastases and explaining the impact on staging and treatment. It adds relevant detail about multidisciplinary evaluation and diagnostic considerations, but does not explicitly state that biopsy-proven synchronous lesions should be managed as synchronous primaries, which is a minor omission."
  },
  "517": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies nintedanib and its inhibition of VEGF, PDGF, and FGF receptors, and highlights PDGFR as significant, but it omits the reference answer’s key fact—CSF1R inhibition—as a significant molecular target, resulting in a moderate omission."
  },
  "518": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 inhibition by azole antifungals and the resulting increased vasoconstriction, but incorrectly identifies the headache medication as a triptan rather than dihydroergotamine, missing the key drug class and mechanism specific to the reference answer."
  },
  "519": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly explains the deviation from standard management due to immunosuppression, and provides relevant rationale without inaccuracies or omissions."
  },
  "520": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical facts, correctly explaining how the location of separate pulmonary nodules affects staging and management, with no inaccuracies or omissions."
  },
  "521": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the drug and lists the relevant inhibited receptors, but incorrectly states that PDGFR, not VEGFR, plays the central role, which is a moderate factual error regarding the reference answer's emphasis."
  },
  "522": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that ALK inhibitor therapy can be started based on the ALK result without waiting for broad profiling, and any additional content is correct and clinically relevant."
  },
  "523": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and adds relevant points about restaging and stage IV disease without any inaccuracies or omissions."
  },
  "524": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that endocrine therapy is reasonable even for tumors ≤0.5 cm, and adds relevant, accurate context about individualized decision-making without any inaccuracies or omissions."
  },
  "525": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, acknowledging the rarity of the mutation and the potential for EGFR-targeted therapy, but it overstates the appropriateness of EGFR inhibitors as a primary option and does not clearly state that platinum-based chemotherapy remains the preferred standard, which is a significant omission."
  },
  "526": {
    "score": 3.0,
    "explanation": "3: The answer covers most key facts, including the diagnosis, relevant agents, and mentions physiochemical alteration, but it overemphasizes antifungal effects and microbial colonization rather than focusing on the primary mechanism of altering the scalp's chemical environment as in the reference. Minor inaccuracies in mechanism attribution prevent a higher score."
  },
  "527": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly identifies Exportin 1 (XPO1) as the target instead of MATE2-K, and provides inaccurate mechanistic details, missing the key fact and introducing confusion."
  },
  "528": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly identifies the drug and its general mechanism, and explicitly states that the exact cellular and molecular details remain incompletely understood; however, it provides more mechanistic detail than the reference, which is not incorrect or irrelevant, so only a minor wording inaccuracy is present."
  },
  "529": {
    "score": 3.0,
    "explanation": "3: The model answer provides a plausible immunomodulatory mechanism for interferons in wart treatment but fails to emphasize that the precise cellular or molecular mechanism is unknown, as required by the reference. It covers some relevant background but omits the key fact that the mechanism is not clearly established."
  },
  "530": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing direct enzymatic replacement and restoration of deficient lysosomal enzyme activity, with additional correct and relevant details specific to Gaucher disease."
  },
  "531": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, acknowledging that neoadjuvant therapy is an option and listing its benefits, but incorrectly states that primary surgery is typically prioritized and that neoadjuvant therapy is not indicated by standard criteria, which is a moderate factual inaccuracy."
  },
  "532": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that the precise mechanism is not fully elucidated but adds speculative mechanisms (ROS generation, mitochondrial interference) that go beyond the reference's \"unknown\" and may imply more certainty than warranted; however, no clinically dangerous advice is given."
  },
  "533": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the drug class as PCSK9 inhibitors, which do not inhibit an enzyme upstream of HMG-CoA reductase, missing the key fact that the question describes enzyme inhibitors (specifically, ATP citrate lyase inhibitors like bempedoic acid); the explanation is otherwise relevant but contains a moderate factual error."
  },
  "534": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the appropriateness of broad molecular profiling, the relevance for both adenocarcinoma and large cell histology, and the recommendation for re-biopsy or liquid biopsy if tissue is insufficient, with no inaccuracies or omissions."
  },
  "535": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on the hormone's receptor (calcitonin receptor) rather than the downstream structural macromolecules (e.g., collagen) that directly determine bone strength, missing the key fact required by the question; it also provides some relevant background but ultimately identifies the wrong category of molecular targets."
  },
  "536": {
    "score": 3.0,
    "explanation": "3: The model answer acknowledges that the precise mechanism against cutaneous parasites is not clarified, which is the key fact, but it adds detailed mechanisms of povidone-iodine's general antimicrobial action that are not specifically established for parasites, making the answer less precise than the reference. No unsafe statements are present."
  },
  "537": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies aminoglycosides as the adjunct, accurately describes their mechanism as protein synthesis inhibitors, and explains their synergistic use with penicillin in enterococcal endocarditis, covering all key clinical facts without error."
  },
  "538": {
    "score": 2.0,
    "explanation": "2: The answer correctly identifies interferon and its receptor-mediated JAK-STAT signaling, but incorrectly names MHC class I as the primary mediator instead of the interferon alpha receptor complex, which is a moderate factual error."
  },
  "539": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on phospholipase A2 inhibition by corticosteroids, which is upstream of lipoxygenase, but does not mention lipoxygenase inhibition as required by the reference. It omits the key fact that the anti-inflammatory effect is achieved via lipoxygenase inhibition, covering less than 70% of the key facts."
  },
  "540": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that BRAF V600E detection implies some molecular testing and that broad profiling is ideal, but it omits the critical point that BRAF V600E is rare in squamous cell carcinoma and its identification typically requires comprehensive profiling; it also equivocates on whether broad profiling has occurred, missing the reference's emphasis that such profiling is implied."
  },
  "541": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly prioritizing concurrent chemoradiation and noting surgery may follow if feasible, but is less explicit than the reference about chemoradiation being the standard initial approach and slightly overemphasizes the possibility of initial surgery, which could cause minor confusion."
  },
  "542": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly identifying the clinical scenario, the use of recombinant cytokine therapy, and its immunomodulatory effects, but it gives \"immunomodulators\" instead of the more precise \"biological response modifiers\" as the drug class, which is a minor inaccuracy in terminology."
  },
  "543": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class as ATP synthase inhibitors and provides accurate, relevant detail about the mechanism and example drug, but it does not explicitly use the broader class term \"enzyme inhibitors\" as in the reference, representing a minor omission in scope."
  },
  "544": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, emphasizes the need for pathologic confirmation, explains the limitations of radiology, and correctly mentions appropriate diagnostic techniques; there are no inaccuracies or omissions."
  },
  "545": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly suggests that immediate switching to targeted therapy is appropriate and does not clearly recommend completing the initial systemic therapy, which is a moderate factual error. It also introduces ambiguity and lacks the clear guidance provided in the reference answer."
  },
  "546": {
    "score": 2.0,
    "explanation": "2: The model answer does not mention iron chelating activity, which is the key pharmacological property referenced; instead, it focuses on AMPK activation, which is not the mechanism described in the question. This represents a moderate omission and a mismatch with the reference answer."
  },
  "547": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies that olaparib is contraindicated due to renal impairment and provides appropriate reasoning, but it inaccurately states the contraindication threshold as eGFR <51 rather than <40 mL/min/1.73 m², which is a minor inaccuracy in wording. The suggestion of alternative treatments is relevant and not penalized."
  },
  "548": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes EGFR-targeted systemic therapy over palliative radiotherapy, missing the key point that urgent local brain-directed treatment is prioritized in symptomatic, diffuse CNS disease; while it provides relevant background and nuances, this is a moderate factual error regarding initial management."
  },
  "549": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference by recommending immediate switch to a TRK inhibitor, which is not standard practice and could be unsafe; this is a major inaccuracy."
  },
  "550": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that surveillance frequency is the same for both groups, missing the key fact that radiotherapy patients require more intensive (every 3–6 months) imaging; this is a major inaccuracy."
  },
  "551": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the standard classification of M1a as metastatic disease and the need for multidisciplinary evaluation to distinguish synchronous primaries. However, it does not clearly state that if both lesions are potentially curable, management as two primaries is appropriate, which is the key point in the reference answer."
  },
  "552": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies thioredoxin reductase as the inhibited enzyme and explains its role in redox balance and immunomodulation, but it omits the specific mitochondrial isoform (Thioredoxin Reductase 2) mentioned in the reference answer."
  },
  "553": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies blockade of nicotinic acetylcholine receptors at autonomic ganglia and explains the physiological consequences, but does not explicitly state \"noncompetitive antagonism,\" which is a key mechanistic detail in the reference answer."
  },
  "554": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing non-surgical local therapies due to high perioperative risk, and adds relevant, accurate context about multidisciplinary assessment and individualized decision-making."
  },
  "555": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the interferon gamma receptor complex instead of the interferon alpha receptor complex, which is a moderate factual error, though it otherwise describes the mechanism and context accurately."
  },
  "556": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies eltrombopag and the thrombopoietin receptor (c-Mpl) instead of interferon alpha and its receptor complex, missing the key fact about the therapy and its molecular target, though it correctly discusses JAK-STAT signaling and is otherwise relevant."
  },
  "557": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant background but incorrectly states that platinum-based chemotherapy is preferred over EGFR-targeted therapy in this setting, omitting the key fact that EGFR-targeted therapy is prioritized for EGFR-mutant cases regardless of histology; this is a moderate factual error."
  },
  "558": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that RET-targeted therapy is a valid first-line option in squamous NSCLC with RET rearrangement, disregarding the exclusion of squamous histology from current standard recommendations; this is a major inaccuracy with potential clinical implications."
  },
  "559": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cytochrome P450 inhibition as the relevant mechanism and mentions triclabendazole, but it does not specify the key isoform (CYP2A6) as in the reference answer, which is a significant omission. Otherwise, the explanation is accurate and relevant."
  },
  "560": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies narcolepsy and explains the mechanism of increased wakefulness via monoamine reuptake inhibition, but incorrectly focuses on dopamine rather than norepinephrine, which is the key fact in the reference answer. The rest of the explanation is accurate and relevant."
  },
  "561": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale, and appropriately discusses standard management options without any inaccuracies or omissions."
  },
  "562": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that MRI is mandatory for assessing local invasion in T4 tumors abutting the subclavian vessels, regardless of unremarkable CT/PET findings, and incorrectly suggests MRI can be omitted unless CT is equivocal, which is a moderate factual error."
  },
  "563": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug as an indirect factor Xa inhibitor and explains its mechanism via antithrombin, but it omits the key reference to \"serine proteinase inhibitors (serpins) potentiators,\" which is central to the reference answer."
  },
  "564": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that grade 3 alone does not usually justify comprehensive regional nodal irradiation, omitting the key fact that grade 3 is sufficient for consideration per guidelines; this is a moderate factual error, though the rest of the content is relevant."
  },
  "565": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on FXR activation and CYP7A1 downregulation, which are related but does not mention the key process of increased hepatic fatty acid β-oxidation as specified in the reference; this is a moderate omission, covering less than 70% of key facts."
  },
  "566": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies prostaglandin receptors and their subclass (EP receptors) as the target, but ultimately names \"G protein-coupled receptor\" as the class, which is less specific than \"prostaglandin receptor agonists\" and omits the key fact that the primary class is prostaglandin receptors; otherwise, the explanation is accurate and relevant."
  },
  "567": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that adjuvant endocrine therapy should be considered despite favorable features, and adds relevant context about prognosis and shared decision-making without inaccuracies or omissions."
  },
  "568": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, acknowledging the lower frequency of actionable mutations and the potential benefit in select cases, but it incorrectly suggests that comprehensive profiling is not generally recommended in advanced squamous NSCLC, which omits the current guideline that recommends profiling when adequate tissue is available."
  },
  "569": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains staging, operability, and standard management, and adds relevant, correct details about treatment options without any inaccuracies or omissions."
  },
  "570": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and explains the mechanism, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference; it also mentions COX-2, which is less relevant here, making this a minor inaccuracy."
  },
  "571": {
    "score": 5.0,
    "explanation": "5: Fully correct; identifies cyclooxygenase (COX) as the molecular target, explains its role in converting arachidonic acid to prostaglandins, and links this to the anti-inflammatory effect. No omissions or inaccuracies."
  },
  "572": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that a 3–6 month follow-up CT is indicated for a 6 mm subsolid nodule, and provides additional relevant, accurate context without any inaccuracies or omissions."
  },
  "573": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug and its mechanism but does not use the reference class \"nucleic acid synthesis inhibitors,\" instead focusing on \"mitochondrial electron transport chain inhibition,\" which is mechanistically accurate but misses the key classification required by the question."
  },
  "574": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes beta-adrenergic receptor agonism and its downstream effects, but omits the key fact that dopamine itself (not just beta-agonists like isoproterenol) is the prototypical drug used in this scenario, and does not mention dopamine receptor stimulation or the dose-dependent nature of dopamine's receptor activity."
  },
  "575": {
    "score": 2.0,
    "explanation": "2: The model provides plausible but unproven mechanisms for gentian violet’s antifungal action, whereas the reference clearly states the mechanism is unknown; this is a moderate factual error and overstates current knowledge."
  },
  "576": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that RET-targeted therapy is appropriate as first-line treatment in squamous cell carcinoma, overlooking the lack of supporting evidence and current guidelines for this histology; it covers some relevant background but omits the key fact that standard chemotherapy/immunotherapy remains preferred, constituting a moderate factual error."
  },
  "577": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that omission of ALND after neoadjuvant therapy is not standard and is under investigation, but it equivocates and suggests omission \"might be considered,\" which is misleading and omits the clear guideline that ALND omission is not currently appropriate in this scenario."
  },
  "578": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies Gentian Violet and notes that its precise mechanism is incompletely understood, but it adds speculative mechanisms (DNA binding, cell wall disruption) not established as definitive, which goes beyond the reference's \"unknown\" and may mislead; overall, it covers most key facts but with minor inaccuracies."
  },
  "579": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the drug (abatacept) and its mechanism but incorrectly states the primary molecular target as the CD28-CD80/86 interaction rather than CTLA-4, which is the reference answer; this is a moderate factual inaccuracy."
  },
  "580": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that immediate annual low-dose CT is standard, directly contradicting the reference, and omits the required initial intensive surveillance phase; this is a major inaccuracy."
  },
  "581": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly suggests that endocrine therapy alone can be appropriate in this scenario, which contradicts current evidence supporting chemotherapy benefit in premenopausal women with a recurrence score of 16–25; it also introduces nuanced decision-making and ovarian suppression, which, while relevant, do not align with the strong recommendation for chemotherapy in this group."
  },
  "582": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that platinum-based chemotherapy is necessary and immunotherapy monotherapy is inadequate, with accurate and relevant explanation regarding PD-L1 status and treatment rationale."
  },
  "583": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizes surgery for resectable recurrence in fit patients, and adds relevant, accurate context about patient selection and multidisciplinary decision-making without any inaccuracies or omissions."
  },
  "584": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly states that concurrent chemoradiation is generally preferred, whereas the reference specifies that both approaches are equally acceptable with no proven superiority; however, it does mention patient factors, covering most key facts but with a moderate factual inaccuracy regarding preference."
  },
  "585": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly prioritizes osimertinib over durvalumab due to EGFR mutation, and provides relevant, accurate explanations without any inaccuracies or omissions."
  },
  "586": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the appropriateness of SRS and surgical resection in certain scenarios, but it does not clearly state that SRS alone is sufficient unless the lesion is symptomatic or tissue diagnosis is needed. It overemphasizes surgical resection as potentially prioritized without specifying the reference's criteria, leading to minor omissions and some ambiguity."
  },
  "587": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and explains its role, but does not specify COX-2 (prostaglandin G/H synthase 2) as the primary isoform relevant to the reference answer, resulting in a moderate omission."
  },
  "588": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly notes the mechanism is incompletely characterized, and provides relevant, accurate additional details; there is a minor overemphasis on possible mechanisms, but no clinically significant inaccuracies or omissions."
  },
  "589": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but overemphasizes the impact of anatomical location on surgical eligibility, implying it may preclude surgery in T4 cases, which is not accurate per the reference. It also introduces complexity and individualized assessment as distinguishing factors, which, while relevant, slightly misrepresents the reference's assertion that anatomical location alone does not preclude surgery."
  },
  "590": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that SLN mapping and excision are appropriate, and provides relevant, correct context from guidelines and clinical trials without any inaccuracies or omissions."
  },
  "591": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but incorrectly states that unresectable local disease is managed with radiotherapy, rather than clarifying that only patients with localized, non-metastatic, and potentially radiotherapy-amenable disease are considered; it does not explicitly exclude patients with disseminated or truly unresectable disease from local therapy, which is a moderate omission."
  },
  "592": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PPARs as the primary target instead of thyroid hormone receptors, which is a moderate factual error; while the explanation is relevant, it misses the key fact required."
  },
  "593": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that the precise mechanism is not fully understood and correctly identifies UDCA as the first-line treatment, but it provides speculative mechanisms that go beyond the reference's \"unknown\" stance; while these are plausible, they introduce minor inaccuracies regarding the certainty of mechanism, slightly exceeding the reference's scope."
  },
  "594": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant radiation therapy is generally considered and that observation alone is typically not sufficient, which contradicts guidelines for stage IB (T2a, N0) NSCLC with R1 resection; this represents a moderate factual error and omits the option of re-resection, covering less than 70% of key facts."
  },
  "595": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies inhibition of folate synthesis via PABA antagonism and provides accurate, relevant details about the drug and enzyme involved, but includes extra mechanistic detail and a minor inaccuracy by implying the antibacterial effect is directly responsible for the anti-inflammatory benefit, which is not the primary therapeutic mechanism in autoimmune disease."
  },
  "596": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the importance of reassessing HER2 status due to possible changes and its influence on treatment, but incorrectly states that confirmation is not strictly necessary and suggests treatment may proceed without biopsy, which omits the reference's emphasis on the necessity of confirmation per best practice."
  },
  "597": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately distinguishing recommendations by menopausal status, noting the need for individualized decision-making in postmenopausal women, and correctly stating that aromatase inhibitors are not effective in premenopausal women without ovarian suppression. No inaccuracies or omissions are present."
  },
  "598": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that chemotherapy can be given in the late third trimester, whereas the reference specifies it should be deferred until after delivery; while the answer provides relevant background and multidisciplinary considerations, it omits the key fact that systemic therapy is postponed in this scenario, constituting a moderate factual error."
  },
  "599": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pre-mRNA splicing machinery as the target and explains the mechanism, but initially emphasizes \"small molecules\" as the target class, which is less precise than the reference's focus on the spliceosome components; however, it ultimately clarifies the correct molecular target, with only a minor wording inaccuracy."
  },
  "600": {
    "score": 3.0,
    "explanation": "3: The model answer provides a general and accurate description of vitamin K’s role in coagulation but does not address the key fact that the precise mechanism by which menadiol benefits patients with inherited Factor II deficiency is not clearly defined, as stated in the reference."
  },
  "601": {
    "score": 3.0,
    "explanation": "3: The model answer correctly notes that ROS1 rearrangements are more common in non-squamous histologies and that confirmation is important, but it overstates the appropriateness of ROS1-targeted therapy in squamous cell carcinoma without emphasizing that squamous histology is generally an exclusion except in rare, specific circumstances, omitting a key clinical nuance."
  },
  "602": {
    "score": 5.0,
    "explanation": "5: Fully covers all key facts from the reference answer, correctly identifies cyclooxygenase inhibition as the drug action, and provides accurate, relevant explanation without any errors or omissions."
  },
  "603": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies somatostatin receptor 2 (SSTR2) as the molecular target, whereas the reference specifies the interferon alpha receptor complex; this is a moderate factual error, though the rest of the explanation is relevant."
  },
  "604": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the contralateral nodule as stage IV (M1a), and appropriately recommends metastatic disease management, with no inaccuracies or omissions."
  },
  "605": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as beta-lactam antibiotics and accurately describes their mechanism, but it does not use the broader term \"enzyme inhibitors\" as in the reference; however, all key clinical facts are present and the explanation is clinically relevant."
  },
  "606": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that FDG-PET/CT is indicated for a new nodule during surveillance, whereas the reference specifies that routine PET/CT is not recommended unless there is suspicion of recurrence; the model conflates routine surveillance with workup of a new abnormality, missing the key point about routine imaging, and thus covers only part of the key facts."
  },
  "607": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the impact of COPD and decreased pulmonary function on surgical candidacy, and appropriately discusses alternative non-surgical options without any inaccuracies or omissions."
  },
  "608": {
    "score": 4.0,
    "explanation": "4: The model answer correctly describes the RNA interference mechanism and its clinical relevance, covering over 90% of key facts, but does not explicitly use the term \"nucleic acid synthesis inhibition\" as in the reference answer, which is a minor wording inaccuracy."
  },
  "609": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly applies the Z0011 criteria to a patient who received neoadjuvant therapy, omitting the key fact that Z0011 does not apply in this context; this is a moderate factual error, though the rest of the content is relevant and not unsafe."
  },
  "610": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the elevated risk due to smoking and pulmonary fibrosis and advises caution about discontinuing follow-up, but it equivocates by suggesting individualized decisions and multidisciplinary discussion rather than clearly stating that discontinuation is not appropriate, as in the reference."
  },
  "611": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, emphasizing the importance of distinguishing between primary tumors and metastases and allowing for curative treatment if both are potentially resectable. It adds relevant detail about diagnostic evaluation but introduces some ambiguity by not clearly stating that, in this scenario, management as two primaries is preferred, resulting in a minor omission."
  },
  "612": {
    "score": 3.0,
    "explanation": "3: The model answer correctly explains the role of vitamin A in synthesizing 11-cis-retinal and restoring night vision, but it omits the key mechanistic detail that the therapeutic effect specifically depends on enzymatic conversion (enzyme interactions), which is central to the reference answer."
  },
  "613": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug class (beta-lactam antibiotics) and accurately describes the mechanism, but it does not directly state the broader pharmacological class \"enzyme inhibitors\" as required by the reference answer, covering about 70-89% of key facts."
  },
  "614": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing selpercatinib or pralsetinib over cabozantinib and providing relevant, accurate explanations without any omissions or inaccuracies."
  },
  "615": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PDGFR instead of CSF1R as the key macrophage receptor, omitting the specific reference answer's fact, though it correctly describes nintedanib's general mechanism and other targets."
  },
  "616": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that FDG-PET/CT and brain MRI are not routinely indicated in asymptomatic patients without evidence of disseminated disease, and provides relevant, accurate context about when these modalities may be considered."
  },
  "617": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains the mechanism, but does not specifically name COX-1 as the primary target, instead mentioning both COX-1 and COX-2; this is a minor omission in specificity."
  },
  "618": {
    "score": 1.0,
    "explanation": "1: The model answer recommends an immediate switch to selpercatinib, which contradicts the reference guidance to complete current first-line therapy before initiating selpercatinib; this is a major inaccuracy and could lead to inappropriate treatment sequencing."
  },
  "619": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the importance of triple-negative status and nodal involvement in guiding chemotherapy, but it omits the reference's key point that uncommon subtypes like tubular carcinoma may require further pathological risk assessment due to distinct prognosis and may not always follow standard protocols."
  },
  "620": {
    "score": 3.0,
    "explanation": "3: The answer correctly explains the mechanism of heparin and its interaction with antithrombin III, but it incorrectly identifies antithrombin III as the primary molecular target, rather than thrombin (via antithrombin III activation), which is the key fact in the reference answer."
  },
  "621": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the target and explains aspirin's mechanism, but does not specify COX-2 as the most directly relevant isoform for anti-inflammatory effects, which is a minor omission."
  },
  "622": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies heparins as the class, accurately explains their mechanism via antithrombin III and thrombin inhibition, and covers all key clinical facts from the reference answer without inaccuracies or omissions."
  },
  "623": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly states that adjuvant HER2-directed therapy is indicated regardless of pCR or nodal status, and appropriately notes pertuzumab is especially considered for initially node-positive cases; all additional content is accurate and clinically relevant."
  },
  "624": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing re-resection when feasible and describing chemoradiation as an alternative; all additional explanations are accurate and clinically relevant."
  },
  "625": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies botulinum toxin and explains its mechanism, but \"neurotoxin\" is less precise than \"acetylcholine release inhibitors,\" omitting the key pharmacological class required by the question."
  },
  "626": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that 1 year of trastuzumab is still indicated regardless of pathological complete response, and provides correct, relevant rationale without any inaccuracies or omissions."
  },
  "627": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on phospholipase A2 inhibition rather than lipoxygenase, omitting the direct inhibition of leukotriene synthesis by lipoxygenase inhibition as specified in the reference. While mechanistically related, this is a moderate factual omission regarding the enzyme class most directly inhibited."
  },
  "628": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine brain MRI is not recommended without neurological symptoms, and appropriately describes standard surveillance and indications for brain imaging. No inaccuracies or omissions are present."
  },
  "629": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the need for absence of distant metastasis, and adds relevant, accurate details about staging and management without any inaccuracies or omissions."
  },
  "630": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that both lesions must be individually curable to justify treating them as two primaries, instead focusing on diagnostic criteria and multidisciplinary considerations; this is a moderate omission that misses the central clinical requirement."
  },
  "631": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that systemic therapy is not recommended for ECOG 3 and that best supportive care should take precedence, with additional relevant explanation and no inaccuracies."
  },
  "632": {
    "score": 2.0,
    "explanation": "2: The model answer does not identify the GABA B receptor as the primary molecular target, instead focusing on enzymes involved in GABA metabolism and other mechanisms of valproic acid. This represents a moderate omission of the key fact required by the reference answer."
  },
  "633": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies demeclocycline and provides relevant clinical context, but it incorrectly names \"antibiotic, specifically within the tetracycline class\" as the broad pharmacological class, rather than \"protein synthesis inhibitors\" as required by the reference answer. This represents a minor but meaningful omission in mechanism-based classification."
  },
  "634": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies glucocorticoids as the pharmacological class and accurately describes their mechanism, but it omits the specific term \"glucocorticoid receptor agonists\" as in the reference answer; otherwise, it covers all key facts."
  },
  "635": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of proposed mechanisms but fails to directly state that the mechanism is unknown, as required by the reference answer; it covers most key facts but omits the central point that the precise molecular interaction is not fully understood."
  },
  "636": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies DNA polymerase as the principal target, correctly explains the mechanism, and links it to cidofovir; no inaccuracies or omissions."
  },
  "637": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that the drug acts as an enzyme inhibitor affecting parasite energy metabolism, but it over-specifies the mechanism (fumarate reductase, mitochondrial electron transport) and drug class (benzimidazoles), which are not directly supported by the reference. This introduces minor inaccuracies and distracts from the general answer of \"enzyme inhibitors.\""
  },
  "638": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies COX-2 as the molecular target, explains its inducible nature and role in prostaglandin synthesis, and accurately contrasts it with COX-1, matching all key clinical facts in the reference without errors or omissions."
  },
  "639": {
    "score": 2.0,
    "explanation": "2: The model answer covers some relevant surveillance details but incorrectly downplays the role of initial radiotherapy as the key determinant for more intensive follow-up, which is a moderate factual omission, and instead emphasizes other factors not central to the reference answer."
  },
  "640": {
    "score": 2.0,
    "explanation": "2: The model answer identifies non-competitive inhibitors as the relevant class, which is a general enzyme inhibition type rather than specifying the key fact—CYP2B6 inhibitors. It also omits the specific isoenzyme (2B6) and provides some correct but non-essential background, covering less than 70% of the key facts."
  },
  "641": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly prioritizing chemoradiation as initial management and acknowledging the role of stenting for urgent symptoms, but is slightly less direct in recommending chemoradiation as the default initial approach and introduces some redundancy regarding patient selection."
  },
  "642": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies cyclooxygenase inhibitors, and provides correct, relevant additional context without any inaccuracies or omissions."
  },
  "643": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise mechanism is incompletely understood and identifies thalidomide, but includes additional mechanistic details (e.g., TNF-alpha inhibition) that, while accurate, go beyond the reference's emphasis on the mechanism being unknown; this is a minor wording inaccuracy but does not alter the essential meaning."
  },
  "644": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and clinically relevant details about staging, guidelines, and adjuvant durvalumab, and contains no inaccuracies or omissions."
  },
  "645": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the mechanism of pyrantel pamoate (nicotinic acetylcholine receptor agonism causing depolarizing blockade), but the reference answer specifies cholinesterase inhibition, which is the mechanism of another antihelminthic (e.g., levamisole). Thus, the model covers the clinical context but misses the specific mechanism asked, covering about 70-89% of key facts."
  },
  "646": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the mechanism of retinoids as modulation of gene transcription via nuclear receptors, but it does not mention enzyme interactions as specified in the reference answer, thus missing the key fact required."
  },
  "647": {
    "score": 2.0,
    "explanation": "2: The answer discusses several drug classes and mechanisms, but is unfocused and does not clearly identify \"nucleic acid synthesis inhibitors\" as the primary mechanism, leading to moderate omissions and some irrelevant content."
  },
  "648": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that broad molecular profiling is not routinely required in pure squamous cell carcinoma and highlights exceptions, but it inaccurately associates significant smoking history with increased need for testing (it is minimal smoking history that prompts testing); otherwise, content is accurate and relevant."
  },
  "649": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor-mediated pathway as the primary mechanism, accurately explains the molecular details, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "650": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that PMRT is typically omitted, overlooking that tumor size >5 cm (as in this case) does not meet omission criteria; while it covers some relevant factors, it omits the key fact that size >5 cm is an indication for PMRT, constituting a moderate factual error."
  },
  "651": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for prioritizing osimertinib over durvalumab, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "652": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly emphasizes the importance of molecular profiling before local therapy regardless of symptoms, and provides relevant additional detail. However, it introduces a minor caveat about urgent intervention for severe neurological symptoms, which is not mentioned in the reference and could be seen as a slight deviation, though not clinically incorrect."
  },
  "653": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies ergosterol as the target and accurately describes the mechanism of binding and pore formation, which is the actual action of natamycin; however, it does not mention inhibition of ergosterol synthesis as in the reference, but rather direct binding, which is a minor wording inaccuracy."
  },
  "654": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that severe comorbidities preclude systemic therapy and that careful evaluation is needed, but incorrectly states that the recommendation \"implicitly assumes\" absence of comorbidities, which is not strictly accurate per the reference."
  },
  "655": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on tyrosine kinase inhibitors and their mechanism, which is not the broad mechanistic class described in the reference (\"biological response modifiers\"). It omits the key fact about immune stimulation and enhancement of host defense, and instead provides a moderately relevant but incorrect mechanistic class."
  },
  "656": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that observation is not excluded, and appropriately discusses factors influencing management without inaccuracies or omissions."
  },
  "657": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the role of retinoic acid receptors in regulating gene expression for mucin production and epithelial differentiation, covering ≥90% of key facts. However, it omits explicit mention of direct modulation of epithelial and mucin-related enzymes, which is the focus of the reference answer."
  },
  "658": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies muscarinic (M3) receptors as the primary target, whereas the reference specifies adrenergic beta2-agonists; however, it does correctly describe a mechanism that can enhance trabecular outflow, covering some relevant facts but missing the key receptor class."
  },
  "659": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly suggests that FDG-PET/CT may be appropriate to consider in asymptomatic patients with new radiographic findings, which contradicts the reference's clear guidance that it is not routinely indicated in this scenario; while the answer discusses relevant considerations, it omits the key point that PET/CT should be reserved for cases with clinical suspicion, not all incidental findings."
  },
  "660": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that standard-dose CT (not low-dose, non-contrast CT) is preferred for surveillance and gives appropriate surveillance intervals, but it omits the distinction between the first three years and the subsequent two years, and incorrectly extends 3–6 month intervals to only two years instead of three. It also overstates the necessity of contrast, whereas the reference allows with or without contrast."
  },
  "661": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies nucleoside analogs (such as acyclovir) and their mechanism, which matches the reference's \"DNA polymerase inhibitors,\" but does not explicitly use the term \"DNA polymerase inhibitors\" as the class name; otherwise, all key facts are present."
  },
  "662": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly notes the default staging assumption, and emphasizes the need for thorough evaluation and multidisciplinary input. It omits the explicit statement that curative treatment may be offered if both are deemed primary and independently curable, but otherwise is accurate and clinically relevant."
  },
  "663": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies EGFR instead of IGF-1R as the direct molecular target, which is a moderate factual error, though the rest of the explanation is relevant and not unsafe."
  },
  "664": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies dual HER2 blockade as preferred in node-positive patients, references supporting evidence, and appropriately includes endocrine therapy; additional comments about individualized decision-making are accurate and clinically relevant."
  },
  "665": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the beta-1 adrenergic receptor as the molecular target and provides accurate, clinically relevant explanation consistent with the reference answer, with no omissions or inaccuracies."
  },
  "666": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but underemphasizes that adjuvant systemic therapy is generally indicated for TNBC >0.5 cm, and suggests omission may be appropriate based on individualized factors, which is less aligned with guidelines; it also introduces ambiguity about thresholds and omits the reference's clear stance that omission is not appropriate except in exceptional cases."
  },
  "667": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the principal molecular target and explains its role in prostaglandin synthesis and inflammation, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference answer; this is a minor omission."
  },
  "668": {
    "score": 5.0,
    "explanation": "5: Fully accurate and complete; all key facts from the reference are included, with additional correct and relevant explanation about HDAC inhibition, chromatin structure, and clinical context."
  },
  "669": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine FDG-PET/CT is not indicated, and appropriately describes standard surveillance with chest CT; additional explanations are correct and clinically relevant."
  },
  "670": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for neoadjuvant therapy in TNBC, and provides relevant, correct additional details without any inaccuracies or omissions."
  },
  "671": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the general mechanism of chelation and its therapeutic effect but is nonspecific about the metal involved (iron), does not mention deferoxamine, and omits the prevention of iron-mediated oxidative damage, which are key clinical facts in the reference answer."
  },
  "672": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key clinical facts, correctly stating that ALND is not mandatory and BCS with axillary staging and adjuvant therapy is appropriate, but introduces minor ambiguity by emphasizing isolated tumor cells/micrometastases, which is not strictly necessary for this scenario (macrometastasis in one node is also acceptable per guidelines); otherwise, content is accurate and relevant."
  },
  "673": {
    "score": 2.0,
    "explanation": "2: The model answer recommends switching to an ALK inhibitor immediately upon detection of ALK rearrangement, which contradicts the reference guidance to complete planned systemic therapy first. While it provides rationale for ALK inhibitors, it omits the standard practice and thus contains a moderate factual error."
  },
  "674": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the enzyme inhibited by NSAIDs and explains the mechanism, but does not specify COX-2, which is the more relevant isoform for inflammation; this is a minor omission."
  },
  "675": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the SNARE complex/SNAP-25 as the molecular target, and accurately explains the inhibition of acetylcholine release, matching and expanding on the reference answer with relevant, accurate detail."
  },
  "676": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the upstaging to at least stage IIIA, the shift to multimodal/neoadjuvant therapy, and the contrast with initial surgical management for N0–1; all additional details are correct and clinically relevant."
  },
  "677": {
    "score": 5.0,
    "explanation": "5: All key clinical facts are covered, including the correct mechanism (inhibition of nucleic acid synthesis), relevant context about babesiosis, and clarification of the roles of atovaquone and azithromycin; all additional content is accurate and clinically relevant."
  },
  "678": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the mechanism of heparin and mentions thrombin (factor IIa) as a target, but it broadens the answer to \"serine proteases of the coagulation cascade\" rather than specifically \"thrombin inhibitors,\" and emphasizes both thrombin and factor Xa, which dilutes the focus from the key fact required by the reference answer."
  },
  "679": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies chemical keratolysis and salicylic acid, and notes that the precise cellular and molecular mechanisms are not fully defined, matching the reference. However, it provides more detail than required and could be slightly clearer in directly stating \"unknown cellular or molecular interaction\" as the mechanism-of-action category."
  },
  "680": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 inhibitors instead of CYP2D6 inhibitors as the key concern, which is a moderate factual error, though the explanation is otherwise relevant."
  },
  "681": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, acknowledges the need for urgent radiotherapy in severe cases, and discusses the role of EGFR TKIs, but it inverts the reference's prioritization by generally favoring systemic therapy first, which is a minor but clinically relevant deviation from the reference's clear recommendation to prioritize radiotherapy for symptom control."
  },
  "682": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise mechanism is unknown and provides additional, factually accurate and relevant details about possible mechanisms, with only minor expansion beyond the reference; there are no inaccuracies or unsafe statements."
  },
  "683": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that pathological confirmation is necessary and explaining the limitations of imaging; all additional details are accurate and clinically relevant."
  },
  "684": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the imaging schedule is not identical and explains the rationale for more frequent imaging, covering nearly all key facts. However, it lacks the explicit, guideline-based comparison of \"chest CT every 3–6 months for 3 years\" versus \"every 6 months for 2–3 years,\" making this a minor omission."
  },
  "685": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing the need for comprehensive evaluation to distinguish two primaries from metastasis and the clinical significance of this distinction. It adds relevant details about histology and molecular analysis, but omits the explicit requirement that both tumors must be technically resectable and potentially curable, which is a minor omission."
  },
  "686": {
    "score": 2.0,
    "explanation": "2: The model answer provides a commonly cited but incomplete mechanism (T-type calcium channel inhibition) rather than stating that the precise mechanism is unknown, omitting the key fact that the exact cellular or molecular mechanism remains unclear."
  },
  "687": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate description of the general mechanism of vitamin K in coagulation, but it fails to address the key fact from the reference answer—that the precise cellular or molecular mechanism in premature infants is currently unknown."
  },
  "688": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that brain metastases do not determine the use of capmatinib or tepotinib, and any additional content is factually correct and clinically relevant."
  },
  "689": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine FDG-PET/CT and brain MRI are not indicated, and provides accurate, relevant explanations without inaccuracies or omissions."
  },
  "690": {
    "score": 3.0,
    "explanation": "3: The model answer covers the broad, non-specific antiseptic action of povidone-iodine and its effects on microbial components, but it does not explicitly state that the precise cellular or molecular mechanism is unknown, as required by the reference answer."
  },
  "691": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that isolated ERBB2 testing would suffice, omitting the key fact that broad molecular profiling is the standard and required approach; this is a moderate factual error."
  },
  "692": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, including the indication for brain MRI, the risk of nephrogenic systemic fibrosis with gadolinium in severe CKD, and the use of non-contrast MRI or CT as alternatives. There is a minor inaccuracy regarding the routine indication for brain MRI in stage III NSCLC, but this does not significantly alter the clinical meaning."
  },
  "693": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, including the consideration of adjuvant chemotherapy in small, node-negative TNBC, the contraindication of anthracyclines due to cardiac comorbidity, and the potential for non-anthracycline regimens, with appropriate emphasis on individualized risk–benefit assessment."
  },
  "694": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies psoralen, its DNA intercalation, and UVA activation, but focuses on DNA cross-linking rather than the most direct process—photoabsorption/activation by UVA. While mechanistically accurate, it omits the key fact that photoactivation is the immediate molecular trigger, not DNA cross-linking, and thus only partially addresses the question."
  },
  "695": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that fam-trastuzumab deruxtecan-nxki is an option for HER2-mutant NSCLC and that ECOG 2 is not a strict exclusion, covering ≥90% of key facts. It adds relevant context about individualized decision-making but lacks the explicit statement that ECOG 2 is not an exclusion criterion, which is a minor omission."
  },
  "696": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly states that curative treatment may be appropriate if the lesions are independent primaries, and adds relevant details about diagnostic considerations and multidisciplinary assessment. There is a minor inaccuracy in emphasizing traditional stage IVA management (systemic/palliative) without clearly affirming current practice supports curative intent in this scenario, but this does not alter the overall meaning."
  },
  "697": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly addresses the appropriateness of fam-trastuzumab deruxtecan-nxki in this setting, and adds relevant, accurate information about monitoring, with no inaccuracies or omissions."
  },
  "698": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dopamine receptor antagonism as the mechanism, provides accurate additional context about promethazine, and includes only clinically relevant, factually correct information without omissions or inaccuracies."
  },
  "699": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies nucleoside analogs as the class and explains the mechanism, but does not explicitly state \"DNA polymerase inhibitors\" as in the reference; however, it covers ≥90% of key facts with only a minor wording difference."
  },
  "700": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly stating that N3 involvement generally excludes surgery as initial therapy regardless of PFTs or metastases, and accurately describes standard treatment. However, it introduces the possibility of surgery after chemoradiation in select cases, which, while rare and not standard, is not strictly incorrect but slightly dilutes the absolute exclusion emphasized in the reference."
  },
  "701": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies COX (specifically COX-2) as the primary target and explains the mechanism, but includes mention of COX-1, which is less relevant to the anti-inflammatory effect described; otherwise, it covers all key facts with only a minor wording inaccuracy."
  },
  "702": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that adjuvant radiotherapy is not routine and depends on clinicopathological factors, and emphasizes multidisciplinary assessment; additional details are correct and clinically relevant."
  },
  "703": {
    "score": 2.0,
    "explanation": "2: The model answer identifies thioredoxin reductase as the primary target, which is a plausible but not the reference enzyme (protein kinase C iota type); it covers some relevant mechanisms but omits the specific key fact required and contains a moderate factual inaccuracy regarding the main enzyme inhibited."
  },
  "704": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the need for individualized assessment and alternative strategies if surgery is too risky, but incorrectly states that perioperative therapy is appropriate even with significant PFT impairment, missing the key point that poor pulmonary function generally contraindicates surgery and thus perioperative therapy."
  },
  "705": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately emphasizing the need for pathological confirmation of N2 disease before initiating systemic therapy and explaining the insufficiency of radiographic findings alone, with no inaccuracies or omissions."
  },
  "706": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the mechanism as neuromuscular paralysis via chloride channels (ivermectin), rather than enzyme inhibition, which is the general mechanism referenced; this is a moderate factual error and misses the key fact required."
  },
  "707": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug class and its mechanism but incorrectly states SSTR2 as the primary target, whereas the reference specifies SSTR5; most key facts are covered, but the main factual detail is inaccurate."
  },
  "708": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies hydroxyapatite as the key structural component targeted by the medication, which is a clinically relevant and accurate detail, but it omits mention of collagen and other macromolecules as referenced in the standard answer; otherwise, the explanation is thorough and accurate."
  },
  "709": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies the drug class as prostacyclin (prostaglandin I2) analogs, explains the mechanism, and provides relevant examples without any inaccuracies or omissions."
  },
  "710": {
    "score": 3.0,
    "explanation": "3: The answer provides a detailed discussion of salicylate mechanisms, including anti-inflammatory and keratolytic actions, but does not directly state that the mechanistic classification is \"unknown cellular or molecular interaction\" as required; it instead infers possible mechanisms, missing the key fact that the mechanism is not clearly defined."
  },
  "711": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that surveillance alone is insufficient and that additional local treatment is generally indicated, while also providing accurate, relevant elaboration on treatment options and considerations without any inaccuracies or omissions."
  },
  "712": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies tryptophan hydroxylase as the inhibited enzyme and provides relevant clinical context, but does not specify the isoform \"tryptophan 5-hydroxylase 1\" as in the reference answer, which is a minor omission."
  },
  "713": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts regarding the importance of broad molecular profiling and specifically mentions EGFR, ALK, ROS1, and PD-L1, but omits several additional relevant targets (BRAF, NTRK, MET exon 14 skipping, RET, HER2) included in the reference; otherwise, the content is accurate and clinically relevant."
  },
  "714": {
    "score": 2.0,
    "explanation": "2: The model answer covers the role of oxygen in improving hypoxemia and discusses modulation of hypoxia-inducible factors and ROS, but it omits the key fact of free radical scavenging activity as the pharmacological mechanism, and introduces some irrelevant content about metabolism and antioxidants."
  },
  "715": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that residual radiographic abnormalities after chemoradiation in stage III NSCLC warrant closer or more frequent imaging, regardless of symptoms, and instead incorrectly suggests standard interval imaging is sufficient unless symptoms arise. This is a moderate factual omission that could impact patient care."
  },
  "716": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies thioredoxin reductase as the inhibited enzyme and provides relevant mechanistic detail, but omits specifying the mitochondrial isoform (thioredoxin reductase 2), which is a minor omission."
  },
  "717": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly recommends adjuvant systemic therapy despite significant pulmonary impairment, which is contraindicated due to high risk of toxicity; this is a major inaccuracy with potential for harm."
  },
  "718": {
    "score": 4.0,
    "explanation": "4: The model answer correctly recommends broad molecular profiling and mentions several relevant targets, but omits some key alterations (e.g., ROS1, RET, ERBB2/HER2) and PD-L1 testing, which are specified in the reference. The additional context is accurate and relevant."
  },
  "719": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug class as DNA methyltransferase inhibitors, accurately describes their mechanism, and provides relevant examples, but does not use the broader term \"nucleoside synthesis inhibitors\" as in the reference; this is a minor wording difference, not a factual error."
  },
  "720": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly identifies the drug as a calcineurin inhibitor rather than clioquinol, providing an inaccurate mechanism of action and failing to address the reference answer's key point that the mechanism is unknown; this is a major inaccuracy."
  },
  "721": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant details about high-risk features, and contains no inaccuracies or omissions."
  },
  "722": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting the potential for HER2-targeted therapy and the independence from PD-L1 status, but omits that targeted therapy for ERBB2 mutations in squamous cell carcinoma is investigational and does not override standard PD-L1-driven treatment algorithms, which are central to current clinical practice."
  },
  "723": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the need to prioritize orthopedic stabilization and radiotherapy before systemic therapy, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "724": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds correct and clinically relevant details about pembrolizumab and its efficacy, and contains no inaccuracies or omissions."
  },
  "725": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explaining that surgery is standard but contraindicated with severely impaired pulmonary function, and that SBRT is the preferred alternative; all additional content is correct and clinically relevant."
  },
  "726": {
    "score": 3.0,
    "explanation": "3: The model answer covers the key fact that the exact molecular mechanism is not fully elucidated, but it provides a specific (though widely accepted) mechanism for metronidazole, which is more detail than the reference allows; this introduces a minor inaccuracy in the context of formal pharmacological classification."
  },
  "727": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing endobronchial intervention for symptomatic obstruction before systemic therapy, and provides additional relevant, accurate clinical context without any inaccuracies or omissions."
  },
  "728": {
    "score": 4.0,
    "explanation": "4: The model answer accurately describes the mechanism of glucocorticoids binding cytoplasmic receptors, nuclear translocation, and gene transcription, and relates this to clinical effects. However, it omits explicit mention of mineralocorticoid receptor agonism, which is also a key therapeutic mechanism in primary adrenal insufficiency."
  },
  "729": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that pertuzumab is generally reserved for node-positive or high-risk cases, but it inaccurately downplays the importance of nodal status as a primary determinant for dual anti-HER2 therapy in the adjuvant setting, and introduces ambiguity about pertuzumab use in node-negative disease, which is not standard per guidelines."
  },
  "730": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies \"calcium channel blockers\" as the drug class, covering the main mechanism, but omits the more specific \"L-type\" subtype mentioned in the reference answer."
  },
  "731": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly recommending 3–6 month CT follow-up and acknowledging the increased malignancy risk and assessment complexity in fibrosis. However, it overstates that fibrosis \"influences\" or \"necessitates\" closer surveillance, rather than clarifying that fibrosis does not fundamentally alter the standard interval, which is a minor wording inaccuracy."
  },
  "732": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, adds relevant considerations about patient selection and tolerability, and contains no inaccuracies or omissions."
  },
  "733": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies 5-alpha reductase as the target enzyme and explains its role, but does not specify the type II isoform or the full enzyme name as in the reference answer; otherwise, it is accurate and clinically relevant."
  },
  "734": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the importance of waiting for biomarker results, the potential need for empiric therapy in urgent cases, and the rationale for individualized decision-making; all additional content is accurate and clinically relevant."
  },
  "735": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies GABA_B receptor, explains mechanism, and links to clinical scenario with no inaccuracies or omissions."
  },
  "736": {
    "score": 3.0,
    "explanation": "3: The model answer accurately describes the general mechanism of metronidazole but does not explicitly state that the exact molecular or cellular interactions in deep tissue abscesses are unknown, as required by the reference answer; it instead implies the mechanism is well understood, missing the key nuance."
  },
  "737": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states that routine brain MRI is not indicated in asymptomatic stage I–II NSCLC post-surgery/chemotherapy, and provides correct, relevant context without inaccuracies or omissions."
  },
  "738": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the requirement for comprehensive molecular profiling and adequate tissue sampling, and provides correct, relevant additional context about larotrectinib’s indication."
  },
  "739": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the need for brain MRI and FDG-PET/CT for accurate staging, and explains the rationale without any inaccuracies or omissions."
  },
  "740": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing BRAF/MEK inhibitor therapy in the presence of a BRAF V600E mutation and explaining the rationale. Additional content is accurate and clinically relevant, with no omissions or inaccuracies."
  },
  "741": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly states that monotherapy is not appropriate, recommends platinum-based chemotherapy, and notes that combination chemo-immunotherapy may be considered; all additional details are accurate and clinically relevant."
  },
  "742": {
    "score": 5.0,
    "explanation": "5: The model answer includes all key clinical facts from the reference, correctly emphasizing the necessity of ongoing ovarian suppression and its rationale, with no inaccuracies or omissions."
  },
  "743": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the PMRT recommendation applies regardless of preoperative systemic therapy, missing the key fact that the recommendation is specifically for patients who have not received preoperative therapy, as nodal status post-neoadjuvant therapy may not reflect untreated disease burden."
  },
  "744": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies praziquantel, describes its mechanism via increased calcium permeability through ion channel interactions, and provides clinically relevant detail without inaccuracies or omissions."
  },
  "745": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly prioritizing NTRK inhibitors for NTRK1 fusion-positive NSCLC with brain metastases and noting their intracranial efficacy. It omits explicit mention of the need for urgent radiotherapy in cases of severe neurological symptoms or mass effect, which is a minor omission."
  },
  "746": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing the risks of re-irradiation and prioritizing systemic therapy, but introduces a minor inaccuracy by suggesting concurrent chemoradiation followed by surgery as an option, which is generally not recommended in this context; otherwise, the answer is thorough and clinically sound."
  },
  "747": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies DNA methyltransferase as the enzyme inhibited by hypomethylating agents used in myelodysplastic syndrome, covering the key clinical facts and mechanism. However, it does not specify the exact isoform (tRNA (Cytosine(38)-C(5))-Methyltransferase) as in the reference, representing a minor omission in specificity."
  },
  "748": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately affirms the appropriateness of sequential chemotherapy and radiotherapy regardless of preoperative therapy, and provides additional relevant, correct clinical context without any inaccuracies or omissions."
  },
  "749": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies insulin receptor activation as the mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "750": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting the rarity of EGFR mutations in squamous NSCLC and the limited efficacy of standard EGFR TKIs for exon 20 insertions, but it overemphasizes the potential use of newer agents without adequately stressing that routine EGFR-targeted therapy is not supported in this context, as per guidelines; it also omits the importance of interpreting molecular findings with caution due to possible diagnostic limitations."
  },
  "751": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that stenting is prioritized for severe or unstable cases and that chemoradiation is definitive therapy, but it incorrectly prioritizes chemoradiation over stenting for symptomatic SVC obstruction, omitting that stenting is often preferred for rapid symptom relief even in stable patients."
  },
  "752": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, clearly stating that fam-trastuzumab deruxtecan-nxki requires confirmed ERBB2 (HER2) mutation positivity and is not indicated for patients without this mutation; additional content is accurate and clinically relevant."
  },
  "753": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the class as melatonin receptor agonists, explains the mechanism, and provides relevant, accurate detail without any inaccuracies or omissions."
  },
  "754": {
    "score": 2.0,
    "explanation": "2: The model answer misidentifies the drug as undecylenic acid rather than clioquinol, which is a moderate factual error, though it correctly notes the mechanism is incompletely characterized; about half of the key facts are addressed."
  },
  "755": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies Janus kinase as the primary target, missing the key fact that glucocorticoid receptors are the main target in this scenario; while the explanation is relevant to JAK inhibitors, it does not address the reference answer and constitutes a moderate factual error."
  },
  "756": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts and provides relevant background, but incorrectly states that concurrent chemoradiation is generally preferred postoperatively, which is not supported by guidelines; the reference emphasizes that neither approach is universally preferred, making this a moderate factual inaccuracy."
  },
  "757": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes external-beam radiotherapy alone as the initial management, omitting that concurrent chemoradiation (with or without SVC stenting) is preferred for both symptom relief and tumor control; it covers less than 70% of key facts and contains a moderate factual error regarding the recommended first-line approach."
  },
  "758": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the lack of efficacy of immunotherapy in EGFR-mutant NSCLC, correctly states the indication for amivantamab-vmjw, and appropriately emphasizes platinum-based chemotherapy as first-line; additional content is factually correct and clinically relevant."
  },
  "759": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly emphasizing the primary indication for broad molecular profiling in adenocarcinoma, large cell, and NOS subtypes, and notes the lower yield in squamous cell carcinoma. The only minor issue is the extra detail about PD-L1 testing being recommended across all NSCLC subtypes, which, while accurate, slightly extends beyond the reference but does not alter the core meaning."
  },
  "760": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly suggests adjuvant systemic therapy can be routinely considered regardless of high-risk features, omitting the key point that it is not required in the absence of such features; this is a moderate factual error."
  },
  "761": {
    "score": 3.0,
    "explanation": "3: The answer correctly identifies the clinical scenario, pathogen, and relevant drug (atovaquone), and explains its mechanism, but the final class given (\"inhibition of mitochondrial electron transport\") does not match the reference answer (\"Nucleic Acid Synthesis Inhibitors\"), omitting the key fact required by the question."
  },
  "762": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies cyclooxygenase inhibition as the mechanism, explains the NSAID class, and provides accurate, relevant details about the drug's action with no omissions or inaccuracies."
  },
  "763": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies JAK1/JAK2 as the direct molecular target, rather than tumor necrosis factor (TNF) as specified in the reference. While the explanation is relevant to GVHD management, it omits the key fact and provides a moderate factual error regarding the primary molecular target."
  },
  "764": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and explains the mechanism, but does not specify COX-1 as the primary molecular target as in the reference; it also mentions COX-2, which is less relevant for traditional NSAIDs in osteoarthritis, resulting in a minor omission and slight inaccuracy in focus."
  },
  "765": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends endocrine therapy alone, omitting the key fact that chemotherapy is indicated for premenopausal women with a recurrence score of 24, as per current guidelines; it also misinterprets the TAILORx data for this subgroup, constituting a moderate factual error."
  },
  "766": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the mutual exclusivity of driver mutations, and appropriately details the rationale for ALK inhibitor selection without any inaccuracies or omissions."
  },
  "767": {
    "score": 3.0,
    "explanation": "3: The model answer covers the majority of key facts, correctly describing chloroquine's accumulation in the food vacuole and its downstream effects on DNA/RNA synthesis, but it emphasizes heme polymerization inhibition as the primary mechanism rather than directly stating \"inhibition of nucleic acid synthesis\" as in the reference; this introduces some minor inaccuracy and partial misalignment with the reference answer."
  },
  "768": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing re-resection and appropriately describing adjuvant radiotherapy as an alternative only if re-resection is not feasible, with no inaccuracies or omissions."
  },
  "769": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that surgery alone is inadequate, explaining the need for additional therapy, and specifying chemotherapy and/or radiotherapy as options. All extra content is accurate and clinically relevant."
  },
  "770": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the use of a steroid hormone receptor agonist and describes the mechanism of intracellular receptor-mediated gene transcription, but incorrectly specifies the estrogen receptor rather than the progestational (progesterone) receptor as in the reference answer, representing a moderate factual inaccuracy."
  },
  "771": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, acknowledging that both surgical and radiotherapy patients may follow similar surveillance, but it equivocates by suggesting surveillance specifics \"can vary\" and implies the schedule is \"typically\" for surgical patients, which could mislead; it lacks the clear statement that both groups are eligible per guidelines."
  },
  "772": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the class as \"beta-lactam antibiotics\" and accurately describes their mechanism, but does not explicitly use the broader term \"enzyme inhibitors\" as in the reference; otherwise, all key facts are present."
  },
  "773": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that both tumors do not need to be independently considered potentially curable, which contradicts the key fact in the reference answer; while it provides relevant context and considerations, this represents a moderate factual error."
  },
  "774": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly asserts that perioperative therapy indications exclude Stage IIB, missing the key point that such therapy can apply to both Stage IIB and higher stages; it also overemphasizes nodal involvement and misrepresents staging criteria, leading to a moderate factual omission."
  },
  "775": {
    "score": 2.0,
    "explanation": "2: The model answer does not mention OCT2, the specific transporter referenced in the question and reference answer, and instead focuses on CYP3A4, BCRP, and P-gp, which are not the key clinical facts here; while some general points about drug interactions are correct, the main mechanism and clinical significance related to OCT2 inhibition are omitted."
  },
  "776": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately discusses the need for caution, dose adjustment, and monitoring, and correctly differentiates between larotrectinib and entrectinib in hepatic impairment, with no inaccuracies or omissions."
  },
  "777": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, accurately explains T3/T4 classification, and correctly distinguishes stage IV criteria; all additional details are factually correct and clinically relevant."
  },
  "778": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly emphasizes best supportive care over systemic therapy, and provides relevant rationale without inaccuracies or omissions."
  },
  "779": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug, its target (PBP3), and the mechanism of inhibiting cell wall synthesis, but does not explicitly state that the binding is covalent, which is a key detail in the reference answer."
  },
  "780": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, including the prioritization of concurrent chemoradiation and the role of surgery in selected cases, but it introduces ambiguity by suggesting induction therapy followed by surgery as a general approach, which is not standard for most patients. This wording may confuse the primary recommendation and represents a minor inaccuracy."
  },
  "781": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the class as beta-lactam antibiotics and accurately describes their mechanism, but it omits the broader class \"enzyme inhibitors\" as in the reference; otherwise, all key facts are present."
  },
  "782": {
    "score": 2.0,
    "explanation": "2: The model answer identifies glutamate-gated chloride channels instead of GABA A receptors, which is a moderate factual error, though the mechanism is otherwise described correctly."
  },
  "783": {
    "score": 4.0,
    "explanation": "4: The model answer correctly prioritizes definitive radiotherapy over surgery in medically inoperable stage IIIB NSCLC and accurately explains why surgery is not feasible. However, it omits that SABR may be considered if technically feasible and overstates that SABR is not typically used, which is a minor inaccuracy given evolving radiotherapy techniques."
  },
  "784": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly stating that orthopedic stabilization is generally prioritized before radiotherapy to prevent fracture and facilitate care, but introduces minor nuance about individualization and exceptions, which is reasonable but slightly dilutes the clear prioritization emphasized in the reference. No clinically unsafe or incorrect statements are present."
  },
  "785": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the enzyme target as lanosterol 14α-demethylase (target of azoles) rather than squalene monooxygenase, missing the key fact required by the reference answer; while the mechanistic explanation is accurate for azoles, it does not address squalene monooxygenase inhibition, which is the focus of the question."
  },
  "786": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing surgery if operable, noting non-surgical options if risk is unacceptable, and adds relevant, accurate context about SBRT and multidisciplinary decision-making without inaccuracies or omissions."
  },
  "787": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the rationale for concurrent chemoradiation, acknowledges the role of sequential therapy for less fit patients, and emphasizes individualized, multidisciplinary care without any inaccuracies or omissions."
  },
  "788": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on serotonin receptor interactions (5-HT1B/1D) and omits the key fact that dopamine receptor interactions are most directly relevant, as specified in the reference. While the serotonin discussion is factually correct, it misses the main point and thus covers less than 70% of the key facts."
  },
  "789": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the sodium-chloride symporter (NCC) in the distal convoluted tubule as the primary target, which is the actual mechanism for thiazide-like diuretics, but it does not match the reference answer, which specifies potassium channels. The model covers most key facts but diverges on the specific ion channel, representing a moderate factual discrepancy."
  },
  "790": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, including the general indication for chemotherapy in TNBC with these features, the need to avoid cardiotoxic agents like anthracyclines, consideration of alternative regimens, and the importance of individualized risk assessment; additional content about multidisciplinary discussion is relevant and accurate."
  },
  "791": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly noting that immune checkpoint inhibitor monotherapy can be considered with PD-L1 ≥1% and no actionable mutations, but it overemphasizes the need for combination therapy and overstates concerns about heart failure as a contraindication, which is not supported by guidelines; it also omits that monotherapy remains appropriate if there is no absolute contraindication."
  },
  "792": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the class as dopamine reuptake (uptake) inhibitors, explains the mechanism, and provides relevant context without inaccuracies or omissions."
  },
  "793": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the inhibited enzyme and explains the mechanism, but incorrectly emphasizes COX-2 rather than COX-1, which is specifically named in the reference. It also adds extra but relevant information about NSAIDs, but the inaccuracy regarding the isoform prevents a higher score."
  },
  "794": {
    "score": 4.0,
    "explanation": "4: The model answer correctly states that the precise mechanism is not fully understood and identifies sodium oxybate as the likely drug, but it provides additional mechanistic details (GABA_B agonism, modulation of dopaminergic/noradrenergic systems) that go beyond the reference's \"unknown\" and may imply more certainty than warranted, representing a minor wording inaccuracy."
  },
  "795": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the beta-lactam class and accurately describes the mechanism as inhibition of PBPs involved in peptidoglycan synthesis, aligning with the reference's \"enzyme inhibitors.\" However, it does not explicitly use the term \"enzyme inhibitors,\" which is the key fact in the reference, representing a minor wording inaccuracy."
  },
  "796": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the drug, its mechanism, and the relevant enzyme, but uses \"RNA synthesis inhibitors\" instead of the broader \"nucleic acid synthesis inhibitors\" as in the reference; this is a minor wording inaccuracy that does not alter the clinical meaning."
  },
  "797": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that routine FDG-PET/CT and brain MRI are not indicated, and that surveillance should consist of clinical evaluation and chest CT, with advanced imaging reserved for symptoms or suspicion of recurrence."
  },
  "798": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the inhibition of nucleic acid synthesis, and provides additional correct and relevant context about nucleoside analogs and their use in MDS, with no inaccuracies or omissions."
  },
  "799": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the proteasome as the relevant complex and accurately describes its function, but it omits the specific \"26S\" designation, which is a key detail in the reference answer."
  },
  "800": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that broad molecular profiling is not typically standard in squamous NSCLC and suggests it is generally reserved for non-squamous histologies, omitting the current guideline that recommends such testing in advanced-stage squamous cases if tissue is sufficient; this is a moderate factual omission."
  },
  "801": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine FDG-PET/CT and brain MRI are not indicated in asymptomatic patients, and appropriately emphasizes chest CT and clinical evaluation; additional content is accurate and relevant."
  },
  "802": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies mast cell stabilizers and accurately describes their mechanism, but it does not use the broader class term \"Biological Response Modifiers\" as in the reference, omitting a key classification detail."
  },
  "803": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that follow-up imaging frequency is generally similar regardless of treatment modality, missing the key fact that radiotherapy requires more frequent imaging (every 3–6 months) than surgery (every 6 months). This is a moderate factual omission, though the rest of the content is relevant and not unsafe."
  },
  "804": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on magnesium’s biochemical roles and correction of hypomagnesemia but omits the key pharmacological property—its acid-base activity as a hydrated inorganic salt—thus missing the central point of the reference answer."
  },
  "805": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that 6-monthly CT is sufficient and does not mention that 3–6 monthly imaging is recommended, omitting the key fact that more frequent surveillance is preferred; it also fails to note that 6-monthly alone is insufficient, which is a moderate omission."
  },
  "806": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizes RET-targeted therapy, and adds relevant, accurate details about specific agents, efficacy, and the need for molecular confirmation, with no inaccuracies or omissions."
  },
  "807": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately states surgery as the preferred option, and adds relevant considerations about patient selection and alternatives without any inaccuracies or omissions."
  },
  "808": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes the clinical scenario and the mechanism of action of cantharidin but fails to identify the pharmacologic class as \"enzyme inhibitors,\" instead using the broader and less specific term \"vesicant.\" This misses the key fact required by the question, though the rest of the explanation is accurate and relevant."
  },
  "809": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies NSAIDs as the drug class, explains the mechanism (COX inhibition), and relates it to the clinical scenario without inaccuracies or omissions."
  },
  "810": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly stating that EGFR-targeted therapy remains appropriate despite a KRAS mutation and that the EGFR mutation is the primary driver. However, it omits that amivantamab-vmjw plus lazertinib is indicated regardless of KRAS status, and overemphasizes investigational status, which is a minor inaccuracy given recent approvals."
  },
  "811": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies 5-lipoxygenase inhibition as central, explains the drug's role, and accurately connects the enzyme to leukotriene synthesis, covering all key clinical facts without inaccuracies."
  },
  "812": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing orthopedic stabilization and radiotherapy before systemic therapy, and provides relevant, accurate additional explanation without any omissions or inaccuracies."
  },
  "813": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, provides correct and clinically relevant additional explanation, and contains no inaccuracies or omissions."
  },
  "814": {
    "score": 2.0,
    "explanation": "2: The model answer omits that both completing current therapy or switching are acceptable options and incorrectly states a general preference to switch, which is not supported by guidelines; this is a moderate factual error and misses key nuance from the reference."
  },
  "815": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies enzymes as the principal molecular targets and accurately explains glucose's role in metabolism, but omits mention of transporters, which are also key targets per the reference answer."
  },
  "816": {
    "score": 4.0,
    "explanation": "4: The model answer covers all key facts, correctly states that radiotherapy is appropriate when re-resection is not feasible, and explains the rationale. However, it omits the detail that this is a category 2B recommendation with less robust supporting evidence, which is a minor omission."
  },
  "817": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that comprehensive molecular profiling is presumed regardless of smoking status, and provides relevant, accurate additional context without any inaccuracies or omissions."
  },
  "818": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target enzyme and explains its role in prostaglandin synthesis, but it does not specify COX-2 (prostaglandin G/H synthase 2), which is the key isoform responsible for inflammation, thus missing a key clinical fact."
  },
  "819": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant pembrolizumab is continued for all patients regardless of risk, missing the key fact that it is indicated specifically for high-risk patients; it also omits the requirement for high-risk classification, which is a moderate factual error."
  },
  "820": {
    "score": 5.0,
    "explanation": "5: The model answer accurately states that preoperative systemic therapy is indicated for cT1c, cN0 triple-negative breast cancer and clarifies that this approach is not exclusive to HER2-positive or node-positive disease; all content is correct and clinically relevant."
  },
  "821": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately stating that NTRK1 fusion alone is sufficient to initiate first-line NTRK inhibitor therapy and that additional biomarker results are not required; extra content is correct and clinically relevant."
  },
  "822": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class as \"beta-lactam antibiotics,\" which is accurate and clinically relevant, but it does not use the broader term \"enzyme inhibitors\" as in the reference; this is a minor wording inaccuracy that does not alter the essential meaning."
  },
  "823": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, including the appropriateness of EGFR TKI therapy for these mutations, the importance of distinguishing the cause of poor performance status, and the consideration of supportive care. Additional content is accurate and clinically relevant."
  },
  "824": {
    "score": 3.0,
    "explanation": "3: The model answer covers the mechanism and clinical effect but does not explicitly mention \"demulcent activity,\" the key pharmacological property in the reference; instead, it describes the effect in broader terms (\"lubricating and tear film stabilization\"), which is accurate but omits the precise terminology."
  },
  "825": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the 5-lipoxygenase pathway as the target for leukotriene reduction and provides relevant additional detail, but introduces corticosteroids and phospholipase A2, which, while accurate, are not directly answering the specific question about leukotriene synthesis inhibition, constituting a minor inaccuracy in focus."
  },
  "826": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies pegylated interferon-alpha and its use, but incorrectly names the JAK-STAT pathway as the primary molecular target, omitting the key fact that RNA replicase enzymes are the main target for the described mechanism; otherwise, the explanation is relevant and contains no unsafe advice."
  },
  "827": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the pharmacological class (beta-lactam antibiotics) and accurately describes the mechanism, but does not explicitly use the broader term \"enzyme inhibitors\" as in the reference; otherwise, it covers all key facts."
  },
  "828": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the specific class (beta-lactam antibiotics) and accurately describes the mechanism, but it does not directly answer with the broader class \"enzyme inhibitors\" as in the reference, missing the key general pharmacological classification."
  },
  "829": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that osimertinib is indicated for all squamous cell carcinomas with EGFR mutations, omitting the key fact that EGFR TKIs are generally not recommended for classic squamous histology due to limited benefit, and failing to mention the need for expert pathology review for mixed/ambiguous cases."
  },
  "830": {
    "score": 3.0,
    "explanation": "3: The model answer correctly mentions 5-lipoxygenase inhibitors (the reference answer), but also includes leukotriene receptor antagonists, which do not inhibit leukotriene production but block their action; this is a minor factual inaccuracy, though the main mechanism is addressed."
  },
  "831": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains the rationale, and adds relevant details about systemic therapy options without inaccuracies or omissions."
  },
  "832": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine PET/CT or brain MRI is not indicated, and appropriately describes standard surveillance; additional content is accurate and clinically relevant."
  },
  "833": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 instead of CYP2D6 as the primary enzyme implicated, which is a moderate factual error, though it provides some relevant context about imatinib and drug interactions."
  },
  "834": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizing observation over systemic therapy in the absence of disseminated disease, and adds relevant, accurate details about monitoring and individualized care without any inaccuracies or omissions."
  },
  "835": {
    "score": 0.0,
    "explanation": "0: The model answer incorrectly identifies PDGFRA as the direct molecular target, whereas the reference specifies KIT; this is a major factual error regarding the precise target, despite otherwise accurate explanation."
  },
  "836": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies leucovorin, explains its structural similarity to folic acid, and accurately describes its mechanism of bypassing dihydrofolate reductase to restore folate-dependent synthesis, covering all key clinical facts with no inaccuracies."
  },
  "837": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, emphasizing the importance of pathologic confirmation and listing appropriate biopsy methods, but introduces exceptions (e.g., medically unfit patients) not mentioned in the reference, which could be seen as a minor inaccuracy or omission regarding the strict requirement for pathologic confirmation before systemic therapy."
  },
  "838": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on membrane disruption rather than enzyme interactions, omitting the key mechanism described in the reference. While the explanation is factually correct for quaternary ammonium compounds, it does not address the specific pharmacological class asked for."
  },
  "839": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, emphasizing the need for pathologic confirmation and distinguishing between treatment for stage IIIB and metastatic disease, but it introduces some ambiguity by suggesting systemic therapy may be appropriate without confirmation, which could be misleading; otherwise, it is thorough and accurate."
  },
  "840": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies beta-1 adrenergic receptor antagonism as responsible, and all additional explanation is accurate and clinically relevant."
  },
  "841": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies retinoic acid receptors (RARs) as the primary nuclear receptor, omitting the key fact that the retinoid X receptor (RXR) is directly modulated. While the explanation is relevant, this represents a moderate factual error."
  },
  "842": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly prioritizing TRK inhibitor therapy and explaining the rationale; additional details are accurate and clinically relevant."
  },
  "843": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describing the mechanism as modulation of enzyme-mediated biological processes, and provides additional correct and clinically relevant detail about retinoic acid, nuclear receptors, and gene expression."
  },
  "844": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts but overstates the preference for adjuvant chemotherapy, whereas guidelines consider both observation and adjuvant therapy appropriate; it also omits that adjuvant therapy is not mandated, which is a clinically relevant nuance."
  },
  "845": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies interferon as the agent and describes its immunomodulatory effects, but it does not explicitly name the class \"Biological Response Modifiers,\" which is the key fact required by the question."
  },
  "846": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly stating that adjuvant therapy is generally indicated but that surveillance may be considered in select cases, such as significant response or contraindications. It adds relevant nuance about multidisciplinary decision-making, but slightly overemphasizes pathologic response as a reason for surveillance, which is not standard; this is a minor inaccuracy, so a 4 is appropriate."
  },
  "847": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that routine FDG-PET/CT is not indicated and describes standard surveillance, but incorrectly suggests that routine brain MRI may be reasonable due to prior brain metastasis, which contradicts the reference; this constitutes a moderate factual inaccuracy."
  },
  "848": {
    "score": 4.0,
    "explanation": "4: The model answer correctly explains the mechanism as inhibition of cell wall synthesis via binding to PBPs, but it does not explicitly state \"enzyme inhibition\" as the general class, which is the key fact in the reference answer; otherwise, the explanation is accurate and relevant."
  },
  "849": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that brain MRI is not mandatory in stage II NSCLC, directly contradicting the reference, and omits the key fact that brain MRI is required for accurate staging and treatment planning; this is a major inaccuracy."
  },
  "850": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains its role in prostaglandin synthesis and symptom mediation, but does not specifically name COX-2 (prostaglandin G/H synthase 2) as in the reference; this is a minor omission."
  },
  "851": {
    "score": 2.0,
    "explanation": "2: The model answer focuses on matrix metalloproteinases (MMPs) rather than interleukin-6 antagonists, missing the key cytokine pathway specified in the reference. While the explanation about MMPs is factually correct and relevant to wound healing, it omits the primary mechanism asked in the question, covering less than 70% of key facts."
  },
  "852": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies nucleoside analogs (a subclass of DNA polymerase inhibitors), explains the mechanism of activation by viral kinases, and details inhibition of viral DNA polymerase, with no inaccuracies or omissions."
  },
  "853": {
    "score": 4.0,
    "explanation": "4: The model answer covers ≥90% of key facts, correctly stating that radiotherapy can be considered even if re-resection is feasible, though it emphasizes re-resection as preferred. It omits the specific \"category 2B\" designation and does not explicitly clarify that radiotherapy is not strictly a salvage modality, but there are no major errors or unsafe statements."
  },
  "854": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that mediastinal nodal involvement upstages the disease to IIIB and that management shifts to multimodal therapy, but it inaccurately suggests perioperative therapy may become more viable, which contradicts the reference stating perioperative therapy is generally precluded; this is a moderate factual error."
  },
  "855": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly stating that sentinel lymph node mapping and excision is sufficient after a negative core biopsy, and that ALND is not indicated. Additional content is accurate and clinically relevant."
  },
  "856": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the molecular target and explains its role, but does not specify COX-1 (prostaglandin G/H synthase 1) as in the reference answer; this is a minor omission."
  },
  "857": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts, accurately states that routine brain MRI is not indicated in asymptomatic patients, references current guidelines, and correctly notes that brain imaging is reserved for symptomatic cases; no inaccuracies or omissions."
  },
  "858": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies CYP3A4 instead of CYP2C9 as the key enzyme, which is a moderate factual error, though the rest of the explanation is relevant and accurate."
  },
  "859": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that surveillance intervals are the same for both groups, omitting the key fact that post-radiation patients require more frequent (every 3–6 months) monitoring. This is a major inaccuracy that could lead to under-surveillance and potential harm."
  },
  "860": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the cytochrome P450 system as the relevant hepatic enzyme system but does not specify the 1A isoenzyme as in the reference answer, representing a minor but clinically relevant omission."
  },
  "861": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies vitamin A deficiency and its role in rhodopsin regeneration, but it does not explicitly mention the free radical scavenging (antioxidant) mechanism as the primary way the therapy improves night vision, missing the key mechanistic focus of the reference answer."
  },
  "862": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies proton pump inhibitors as the drug class sharing the molecular target, but introduces confusion by discussing ciclopirox, which does not act via proton pump inhibition, and incorrectly suggests mechanistic overlap, leading to minor factual inaccuracies and partial irrelevance."
  },
  "863": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies phospholipase A2 as the directly inhibited enzyme, omitting lipoxygenase, which is specifically referenced in the question and reference answer; while the explanation is relevant, it misses the key fact and contains a moderate factual error."
  },
  "864": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies inhibition of cyclooxygenase (COX) as the mechanism and explains its role in prostaglandin synthesis, but does not specify COX-2 (Prostaglandin G/H Synthase 2) as in the reference, representing a minor omission."
  },
  "865": {
    "score": 1.0,
    "explanation": "1: The model answer incorrectly states that perioperative therapy is suitable despite severely impaired lung function, which is a major inaccuracy and could lead to unsafe management; it fails to recognize that surgery (and thus perioperative therapy) is contraindicated in this context."
  },
  "866": {
    "score": 2.0,
    "explanation": "2: The model answer does not identify the key reference mechanism—serotonin (5-HT2) receptor antagonism by methysergide—and instead discusses 5-HT1 agonists, CGRP antagonists, and beta-blockers, none of which directly match the reference. While some mechanistic discussion is relevant, the main target and mechanism are omitted, and there is moderate factual inaccuracy regarding the most direct prophylactic mechanism described."
  },
  "867": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly explains why concurrent chemoradiation is inappropriate, and appropriately discusses alternative management options without any inaccuracies or omissions."
  },
  "868": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the mechanism as somatostatin receptor agonism rather than dopamine agonism, which is the reference answer's focus; while the explanation is detailed and relevant for somatostatin analogs, it misses the key fact required and thus covers less than 70% of the reference content."
  },
  "869": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies that the precise molecular mechanism is not fully elucidated and provides accurate, relevant details about the proposed mechanism (calcium influx and paralysis), with no inaccuracies; the only minor issue is that it goes beyond the reference's minimalism, but all extra content is correct and relevant."
  },
  "870": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for brain MRI, and emphasizes its importance for staging and treatment planning without any inaccuracies or omissions."
  },
  "871": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies phospholipase A2 as the most directly inhibited enzyme, omitting the specific reference answer of lipoxygenase inhibition; while it explains corticosteroid action, it misses the key fact required and contains a moderate factual omission."
  },
  "872": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately addresses the impact of COPD and borderline pulmonary function on surgical risk, and appropriately presents radiotherapy as an alternative; additional content is relevant and correct."
  },
  "873": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly stating that M1a disease is metastatic and that standard treatment is systemic therapy, not surgery. However, it introduces the possibility of surgery in select oligometastatic cases, which is not supported by current guidelines for M1a contralateral nodules and may be misleading, representing a minor inaccuracy and overstatement."
  },
  "874": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies chelating activity as the principal pharmacological property and provides relevant context about iron metabolism in certain hereditary spastic paraplegias, but includes some unnecessary detail about specific drugs and mechanisms not strictly required by the reference answer. No major omissions or inaccuracies."
  },
  "875": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key facts, correctly stating that concurrent chemoradiation is not recommended due to high risk, and suggests alternative strategies. However, it introduces surgical resection as a possible option despite severely impaired PFTs, which is not supported in the reference and could be misleading, representing a minor inaccuracy."
  },
  "876": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the requirement for absence of distant metastases, and provides relevant additional context about typical management without any inaccuracies or omissions."
  },
  "877": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies cyclooxygenase (COX) as the molecular target, missing the key fact that the question asks for a cyclic nucleotide signaling enzyme (cGMP-specific phosphodiesterase). While the explanation of NSAID action is accurate, it does not address the specific mechanism described in the question, constituting a moderate factual error."
  },
  "878": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly emphasizes the necessity of systemic therapy, and appropriately discusses HER2-targeted options; all additional content is accurate and clinically relevant."
  },
  "879": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the syndrome, the drug (rhGH), and specifies \"growth hormone receptor agonism,\" which is a precise subclass of pituitary hormone receptor agonists; however, it does not explicitly use the broader class term from the reference answer, representing a minor wording inaccuracy."
  },
  "880": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly implies that adjuvant systemic therapy consideration in stage IB NSCLC depends on the presence of additional high-risk features, whereas the reference states it may be considered even without them; this is a moderate factual error, though the rest of the content is relevant."
  },
  "881": {
    "score": 3.0,
    "explanation": "3: The answer correctly explains the mechanism and clinical context but incorrectly identifies the class as \"muscarinic agonists (cholinomimetics)\" rather than \"cholinesterase inhibitors,\" which is the specific class referenced in the question; this is a minor but important inaccuracy, though the rest of the content is accurate and relevant."
  },
  "882": {
    "score": 3.0,
    "explanation": "3: Identifies the correct drug class (antimalarials) and mechanism, but omits the key fact that the relevant mechanism is as enzyme inhibitors, as specified in the reference answer; otherwise accurate and relevant."
  },
  "883": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the receptor as a nuclear receptor, specifically glucocorticoid receptors, which is accurate and clinically relevant; however, it does not explicitly use the term \"corticosteroid hormone receptors\" as in the reference, representing a minor wording inaccuracy."
  },
  "884": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly suggests that concurrent chemoradiation may still be appropriate despite significant pulmonary impairment, missing the key contraindication due to high toxicity risk; while it discusses multidisciplinary evaluation, it omits the critical point that poor pulmonary function generally precludes this treatment, representing a moderate factual error."
  },
  "885": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that routine brain MRI is not required, describes appropriate surveillance methods, and accurately notes MRI is reserved for symptoms or suspicion; additional context about higher-stage disease is relevant and correct."
  },
  "886": {
    "score": 2.0,
    "explanation": "2: The model answer recommends H&P and chest CT every 6 months, omitting the key fact that adjuvant radiotherapy warrants more frequent imaging (every 3–6 months) as per the reference; this is a moderate omission affecting clinical accuracy."
  },
  "887": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately explains the rationale for chemoradiation, addresses the insufficiency of systemic therapy alone, and includes only relevant, correct additional details."
  },
  "888": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CYP2C9 inhibitors as the relevant class, explains the mechanism of sulfonamides, and accurately links CYP2C9 inhibition to increased warfarin levels, with no omissions or inaccuracies."
  },
  "889": {
    "score": 2.0,
    "explanation": "2: The model answer misses the key point that external-beam radiotherapy in this context typically implies the presence of endobronchial obstruction, locoregional recurrence, or symptomatic local disease, and instead incorrectly generalizes its use to all stage IIIA cases, which is a moderate factual omission."
  },
  "890": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies JAK3 as the molecular target and accurately explains its role in common γ-chain cytokine signaling and the pathogenesis of alopecia areata, with no omissions or inaccuracies."
  },
  "891": {
    "score": 2.0,
    "explanation": "2: The model answer omits the key fact that brain MRI is routinely required for stage II and above, and incorrectly suggests omission is generally acceptable in stage II, which is a moderate factual error; it also overemphasizes symptom-driven imaging, missing the guideline-based standard for asymptomatic patients."
  },
  "892": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly states that osimertinib is appropriate regardless of smoking history or other mutations, and adds only relevant, accurate context without any inaccuracies or omissions."
  },
  "893": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug class (beta-lactams) and describes their mechanism, but it does not specifically mention \"transpeptidase inhibitors,\" omitting the key fact that PBPs are transpeptidases; instead, it gives a more general mechanism (\"inhibition of cell wall synthesis\")."
  },
  "894": {
    "score": 3.0,
    "explanation": "3: The model answer covers the protective coating and pH alteration but emphasizes antisecretory and antimicrobial actions, which are not the primary mechanism referenced; it includes some correct but less relevant details, and only partially addresses the key acid-base activity."
  },
  "895": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX) as the enzyme inhibited by NSAIDs and explains its role, but does not specify the isoform COX-1 (prostaglandin G/H synthase 1) as in the reference answer; otherwise, the explanation is accurate and clinically relevant."
  },
  "896": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interleukin-6 receptor as the molecular target, references tocilizumab, and accurately explains its role in treating giant cell arteritis; all key clinical facts are covered with no inaccuracies or omissions."
  },
  "897": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies cyclooxygenase (COX) as the target and explains the mechanism, but does not specify COX-2 (prostaglandin G/H synthase 2) as in the reference answer, missing a key detail."
  },
  "898": {
    "score": 2.0,
    "explanation": "2: The model answer correctly describes a drug class (prostaglandin analogs) that can be used for vasodilation in peripheral vascular disease, but it does not match the reference answer's focus on adrenergic alpha-antagonists and their mechanism. The explanation of the molecular mechanism is accurate for prostacyclin analogs but is not the mechanism described in the reference, resulting in a moderate factual mismatch."
  },
  "899": {
    "score": 5.0,
    "explanation": "5: Fully covers all key clinical facts from the reference, accurately stating that endobronchial interventions are considered for symptomatic obstruction and not for asymptomatic patients, with additional relevant details about symptoms and palliative intent."
  },
  "900": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD2 as the molecular target, explains its role, and accurately names the relevant drug (alefacept); all key facts are covered with no inaccuracies or omissions."
  },
  "901": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, correctly emphasizing the benefit of ROS1-targeted therapy and the rationale for switching, but it incorrectly implies that completing ongoing systemic therapy is not typically advisable, omitting that both approaches are acceptable per current practice."
  },
  "902": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly noting the efficacy of capmatinib and tepotinib for MET exon 14 mutations and the concerns with severe hepatic impairment. It slightly understates the relative contraindication (using \"requires careful consideration\" rather than clearly stating they are not appropriate), but otherwise provides accurate and relevant detail."
  },
  "903": {
    "score": 3.0,
    "explanation": "3: The model answer covers most key facts, acknowledging the role of radiotherapy for symptom control, but incorrectly states that systemic therapy is generally prioritized, which contradicts the reference's emphasis on radiotherapy for immediate symptom relief; otherwise, the answer is accurate and relevant."
  },
  "904": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies chylomicron formation as the bypassed component, explains the mechanism, and accurately relates it to the clinical scenario, covering all key facts without errors or omissions."
  },
  "905": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies that standard chemotherapy is not generally recommended due to safety and toxicity concerns, and discusses the need for alternative approaches and multidisciplinary input. However, it lacks the explicit statement that significant hepatic impairment is a contraindication to most standard regimens and does not mention the possibility of postponing treatment until liver function improves, representing a minor omission."
  },
  "906": {
    "score": 2.0,
    "explanation": "2: The model answer misidentifies the pharmacological class (glucocorticoid vs. estrogen receptor agonist) and mechanism, focusing on corticosteroids rather than estrogens, which is a moderate factual error. It does, however, correctly describe the clinical scenario and mechanism of corticosteroids, but misses the key fact required by the question."
  },
  "907": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies CYP3A4 as a key cytochrome P450 enzyme inhibited by triazoles and explains the clinical relevance, but omits mention of CYP2C19, which is especially inhibited by voriconazole per the reference; otherwise, the content is accurate and relevant."
  },
  "908": {
    "score": 2.0,
    "explanation": "2: The model answer correctly identifies the general mechanism of resistance (ABC transporter-mediated efflux) and discusses Miltefosine, but incorrectly names P-glycoprotein (P-gp) instead of the specific BCRP (ABCG2) transporter, which is the key fact in the reference answer. This constitutes a moderate factual error."
  },
  "909": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies topoisomerase IV as a target and provides accurate, relevant additional information, but also includes DNA gyrase, which is not the primary target for segregation in this context; this is a minor inaccuracy in wording but does not alter the clinical meaning."
  },
  "910": {
    "score": 4.0,
    "explanation": "4: The model answer covers over 90% of the key facts, correctly noting that curative surgery may be considered if the lesions are separate primaries, and emphasizes the need for thorough evaluation and multidisciplinary review. It slightly overemphasizes the distinction process and does not explicitly state that M1a status due to a solitary contralateral nodule does not preclude curative management, which is a minor omission."
  },
  "911": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, the drug (thalidomide), and its immunomodulatory action, but incorrectly names TNF-alpha as the most direct molecular target instead of VEGF-A, which is specifically referenced in the question."
  },
  "912": {
    "score": 3.0,
    "explanation": "3: The model answer correctly describes defibrotide's mechanism and its use in hepatic sinusoidal obstruction syndrome, but it does not explicitly name \"tissue plasminogen activators\" as the class of agents, which is the key fact required by the question and reference answer."
  },
  "913": {
    "score": 3.0,
    "explanation": "3: The model answer correctly states that switching to crizotinib is appropriate and provides relevant rationale, but it omits that completing the current regimen before switching is also an acceptable option, thus missing a key fact from the reference."
  }
}